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I 
 
Preface 
 
Natural products play a significant role in health care and disease prevention, and many useful 
drugs are developed from natural sources. World Health Organization (WHO) reported that 80% 
population of the world depends on traditional medicine for primary health care.1 Natural 
products research with biological activity guided isolation continues to explore a variety of lead 
structures, which are used as templates for the development of new drugs. More than 3000 plant 
species have been reported to treat cancer and about thirty plant-derived compounds have been 
isolated so far and have been tested in cancer clinical trials.2 Despite outstanding progress in the 
discovery and development of novel cancer therapeutics, cancer remains the second leading 
cause of death in the world.2 Cancer is characterized by the uncontrollable cell growth and 
disruption of intracellular signaling is the central cause to many cancer. Cancer research 
expanded due to the diversity of signaling mechanisms during cancer initiation and progression. 
 
The rising incidence of cancer along with the undesirable side effects observed with 
chemotherapy urges the discovery of new agents from natural sources. Cancer cells exhibit 
deregulation in multiple cellular signaling pathways, yet all cancers share a number of common 
hallmark capabilities, such as genetic instability, self-sufficiency in growth signals, insensitivity 
to anti-growth signals, avoidance of apoptosis, unlimited replication, sustained angiogenesis, 
and tissue invasion and metastasis.3  
 
Cancer chemoprevention by phytochemicals has shown promising results against various 
malignancies.4 Secondary metabolites derived from plants potentially represent an inexhaustible 
source of chemicals for the discovery of new drugs. The actual compound isolated from the 
plant may not directly serve as the drug but leads to the development of potential novel agents. 
Ingenol 3-O-angelate5 obtained from Euphorbia peplus which is used for treatment of skin 
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cancer. Podophyllotoxin6 isolated as an anticancer agent from Podophyllum peltatum in 1944. 
Etoposide and teniposide,7 a semisynthetic derivative of podophyllotoxin, cause apoptosis of 
cancer cells by inhibition of topoisomerase II. The most generally used anticancer drug is 
paclitaxel (Taxol®),5 which was isolated from Taxus brevifolia (Pacific Yew), and it was 
approved by Food and Drug Administration (FDA). 
 
                            
                                       
 
 
Therefore, utilizing specific agents to target single pathways is a tactic that frequently fails in 
cancer therapy. This research was conducted to search for compounds by bioassay guided 
separation with TRAIL-resistance overcoming activity. 
 
 
 
 
 
Paclitaxel Ingenol 3-O-angelate Podophyllotoxin 
Etoposide Teniposide 
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Chapter 1: Introduction 
 
 
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of TNF 
superfamily with 20 KDa and 281 amino acids containing type II trans-membrane protein.1,2 
TRAIL is a potent and selective inducer of apoptosis in tumor cells while sparing normal cells 
makes it an attractive target for the development of new cancer therapy. TRAIL is essential for 
immune surveillance, apoptosis of unwanted cells, and suppression of spontaneous tumor 
formation.2 Apoptosis is a genetically controlled mechanism that is important for the 
maintenance of tissue homeostasis, proper development and the elimination of genetically 
transformed cells. Apoptosis is a distinct morphological and biochemical change in cell that is 
mediated by caspases.3  
 
TRAIL is expressed on the membrane of immune cells and binds at least five receptors. Two of 
these death receptors, DR4 (TRAIL-R1) and DR5 (TRAIL-R2), are transmembrane receptors 
with a cytoplasmic death domain that transmits apoptotic signal into the cells. Two decoy 
receptors, DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4), do not have functional death domain and 
unable to induce apoptosis. TRAIL also binds weekly to a fifth receptors, osteoprotegerin 
(OPG).4 OPG is a soluble receptor that negatively regulates osteoclastogenesis.2 The TRAIL 
receptors DR4 and DR5 not only trigger apoptosis in TRAIL sensitive cells but also activate 
survival pathways in tumor cells that inhibit the induction of apoptosis upon exposure to TRAIL. 
Post-translational modifications such as glycosylation and palmitoylation of DR4 and DR5 death 
receptors are important regulators of TRAIL induced apoptosis.4  
 
There are two essential apoptotic pathways, referred to as the death-receptor (extrinsic) pathway 
and the mitochondrial (intrinsic) pathway. TRAIL can activate either pathway, depending on the 
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cell type. TRAIL-induced apoptosis started after binding of TRAIL with the death-receptors 
(DR4 and DR5), then death receptors homotrimerize and death signal transmitted to cytoplasm 
enabling to recruit adaptor protein Fas-associated death domain (FADD), death-inducing 
signaling complex (DISC) formation, proteolytic activation of caspase-8, and consequently, 
activation of caspase-3 and causing apoptosis (Fig. 1-1). Proteolytic activated caspase-8 further 
activates Bid, which, in turn, translocates to the mitochondria and activates mitochondrial 
pathways.5 In the mitochondrial pathway, cleaved Bid, called truncated Bid (tBid), translocates 
to the mitochondria where it interacts with other proapoptotic members of Bcl-2 family, Bax and 
Bak, that form pores in the outer mitochondrial membrane causing the release of proapoptogenic 
factors such as cytochrome c. Cytochrome c then binds to the adaptor apoptotic protease 
activating factor 1 (Apaf-1) and pro-caspase-9 to form an apoptosome, leading to the activation 
of caspase-9. Activated caspase-9 serves as initiator caspase to activate executioner caspase-3, -6, 
and -7, which causes cell death (Fig. 1-1). There is a crosslink between these two pathways 
through caspase-8 mediated Bid cleavage and subsequent translocation to the mitochondria to 
initiate the intrinsic apoptosis pathways.6  
 
p53, an important tumor suppressor protein that participates in cellular responses to various 
stresses, acts as a transcriptional factor of the proteins involved in the TRAIL signal.7  The p53 
protein plays a significant role in response to various cellular stresses by modulating 
transformation, cell growth, DNA synthesis and repair, differentiation, and apoptosis.5 In the 
extrinsic pathway, p53 can upregulate the expression of Apaf-1 as well as death receptors DR4 
and DR5 and pro-apoptotic mitochondrial membrane proteins Bax and Bak. p53 also decreases 
the expression of certain anti-apoptotic genes such as Bcl-2, Bcl-xl, and survivin.5  However, 
p53 is mutated in 50% of human tumors.8 Previous study has reported that CHOP is involved in 
the induction of DR5 for the potentiation of TRAIL-induced apoptosis.9 CHOP is known to ER 
(endoplasmic reticulum) stress marker protein involved in ER stress-mediated apoptosis.10  
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                                     Fig. 1-1: TRAIL-induced apoptotic pathway 
 
However, it has become a problem that considerable numbers of cancer cells, especially some 
highly malignant tumors, are resistant to apoptosis induction by TRAIL.
5 
For example, lung 
cancer, breast cancer, prostate cancer, gastric cancer, are said to be resistant to TRAIL. TRAIL-
resistance can occur at different points in the signaling pathways of TRAIL-induced apoptosis. 
Decrease expression of the death receptors DR4 and DR5 due to mutations can lead to TRAIL-
resistance. The adaptor protein Fas-associated death domain (FADD) and caspase-8 are essential 
for forming the death-inducing signaling complex (DISC), and defects in either of these 
molecules can lead to TRAIL resistance.6 c-FLIP (cellular FLICE-Like Inhibitory Protein) is an 
antagonist of caspases-8 and -10, preventing the binding of these caspases with DISC and thus 
inhibiting the autolytic cleavage and subsequent activation of caspase-8. c-FLIP is expressed in 
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various tumor cells and its expression is associated with enhanced tumorigenicity and poor 
clinical outcome in many types of cancers because of TRAIL-resistance.11 Over expression of 
Bcl-2 or Bcl-X(L), loss of Bax or Bak function, high expression of inhibitor of apoptosis 
proteins (IAPs), have also been reported to result in TRAIL resistance. Caspase-8 is a critical 
mediator for death receptor-induced apoptosis and GSK-3β suppresses the activity of caspase-8. 
GSK-3β inhibitor induced TRAIL sensitization depends on caspase-8 activities.12 Overcoming 
TRAIL-resistance and understanding the mechanisms underlying such resistance, are, thus very 
important in anticancer drug discovery.  
 
 
Fig. 1-2: Compounds reported to overcome TRAIL-resistance by other research groups 
 
Different chemotherapeutic agents including a number of natural products are reported to have 
TRAIL-resistance overcoming activity. For example, luteolin is a naturally occurring flavone, 
induces apoptosis in various cancer cells. Luteolin significantly enhanced the expression of DR5, 
downregulated the level of Bcl-2 and upregulated the caspase-8, -10, -9, and -3, suggesting that 
DR5 induced by luteolin plays a key role in luteolin-induced apoptosis. In addition, luteolin 
induced neither DR5 protein expression nor apoptosis in normal human peripheral blood 
mononuclear cells, implying that luteolin selectively induces apoptosis in tumor cells.13,14
 
Treatment with luteolin, therefore, might be promising as a new therapy against cancer.
 
Some 
5 
 
phytochemicals such as curcumin,15
 
resveratrol,16
 
apigenin,17 2-methoxyestradiol,18 
flavopiridol,19 indole-3-carbinol,20 azadirone,21 and dibenzylacetone22 have received attention 
recently as anticancer agents, since previous study reported that they induced TRAIL-mediated 
apoptosis in cancer cells (Fig. 1-2). Curcumin sensitizes TRAIL-induced apoptosis in human 
renal cancer (Caki) cells through CHOP-independent DR5 upregulation.23 Azadirone, a limonoid 
tetranortriterpene, induces death receptors and sensitizes human lung cancer (H1299) cells to 
TRAIL-mediated apoptosis through p53 independent mechanism.21  
 
        
Fig. 1-3: Compounds reported to overcome TRAIL-resistance by Prof. Ishibashi research group 
 
In the recent years, Prof. Ishibashi research groups were exploring natural resources in search for 
bioactive natural compounds abrogating TRAIL signaling pathways. Our research groups 
isolated a number of active compounds with TRAIL-resistance overcoming activity, such as 
fuligocandin B,24 parviflorene F,25 1-O-formylrocagloic acid,26 cryptolepine,27 scopadulciol,28 
pannokin D, and artonin E,29 etc (Fig. 1-3). Fuligocandin B was obtained from the myxomycete 
Fuligo candida, and sensitized TRAIL-resistant leukemia cells to TRAIL-induced apoptosis by 
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upregulating COX-2 and 15d-PGJ2.24,30 1-O-formylrocagloic acid was isolated from Amoora 
cucullata, induced TRAIL-mediated apoptosis in human gastric adenocarcinoma (AGS) cells by 
increasing mRNA expression of death receptors DR4 and DR5.26 Artonin E was obtained from 
Artocarpus communis, sensitized AGS cells to TRAIL-induced apoptosis by upregulating DR5 
and p53 protein levels.29 
 
After starting my PhD research work at the Laboratory of Natural Products Chemistry, Graduate 
School of Pharmaceutical Sciences, Chiba University, under the supervision of Prof. M. 
Ishibashi, I continued the ongoing research work on search for bioactive natural compounds 
with TRAIL-resistance overcoming activity. Although a number of natural products have been 
reported with TRAIL-resistance overcoming activity, still we are searching some active 
compounds. In this PhD research report, I shall present the exploration of Bangladesh medicinal 
plants (KKB186 Datura stramonium and KKB255 Xanthium strumarium) and Thailand 
medicinal plants (KKP87 Boesenbergia pandurata) to bioassay guided isolation of compounds 
with TRAIL-resistance overcoming activity.  
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Chapter 2: Assay Protocol 
 
 
Principle:  
TRAIL-resistance overcoming activity of the extracts and compounds were measured by 
comparison of cell growth inhibitory activity in the presence and absence of TRAIL against 
TRAIL-resistant human gastric adenocarcinoma (AGS) cells. Cell growth inhibitory activity of 
the sample was assessed by Fluorometric Microculture Cytotoxicity Assay
 
(FMCA)1 method 
using Fluorescein Diacetate (FDA) as a dye. FDA is a nonfluorescent compound which is 
converted to fluorescent compound after hydrolyzed by the enzyme esterase, produced by the 
viable cells. Thus, the fluorescence intensity is directly proportional to the number of viable 
cells.  
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                        Fig. 2-1: TRAIL-resistance overcoming activity of sample 
 
The blue bar represents the viability of the cells treated with sample and sky color bar represents 
the viability of cells with combined treatment of sample and TRAIL (100 ng/mL) (Fig. 2-1). 
25% difference in viability between in the presence and in the absence of TRAIL indicates 
compounds overcoming TRAIL-resistance and more difference in viability means compound 
with strong TRAIL-resistance overcoming activity.2  
 
Method: 
Cell viability was assessed using a fluorometric microculture cytotoxicity assay (FMCA) in the 
presence and absence of TRAIL using TRAIL-resistant AGS cells. AGS cells were cultured in 
Roswell Park Memorial Institute (RPMI)-1640 medium (Wako, Osaka, Japan) with fetal bovine 
serum (10% FBS) and 1% penicillin-streptomycin. Cultures were maintained in a humidifier 
incubator at 370 C in 5% CO2 / 95% air.2 Cells were seeded in 96-well culture plate (6 x 103 cells 
per well) with 200 µL of cells culture medium in each well. Then cells were incubated at 370 C 
in a 5% CO2 incubator for 24 h. Test samples at different doses with or without TRAIL (100 
Viability 
diff. >25% 
Active Inactive 
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ng/mL) were added to each well. After 24 h incubation, the cells were washed with PBS 
(Phosphate Buffer Saline), and 200 µL of PBS containing fluorescein diacetate (10 µg/mL) was 
added to each well. The plates were incubated at 370 C for 1 h, and fluorescence at 538 nm 
(emission) and at 485 nm (excitation) was measured using Fluoroskan Ascent (Thermo Fisher 
Scientific, Waltham, MA, USA).2-3 Luteolin (purity ≥ 98%, Sigma–Aldrich) was used as a 
positive control.  
 
 
                                                      
                                   
 
                                           
                                                                                                             
                                      
 
 
          Fig. 2-2: Assay Protocols of TRAIL-resistance overcoming activity 
 
 
 
1st Day: AGS cells seeding (96-well plate) 
2nd Day: Sample and sample + TRAIL (100 ng/mL) 
3rd Day: add FDA and measure fluorescence 
Ex: 485 nm & Em: 538 nm 
Fluorometer 
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Chapter 3: Screening of Plant Extracts Library 
 
 
Medicinal plants collected from Bangladesh (KKB) and Thailand (KKP) was screened for 
TRAIL-resistance overcoming activity. In our screening program, about 101 Bangladeshi and 13 
Thailand medicinal plants extract were checked for TRAIL-resistance overcoming activity by 
FMCA method. About 25 Bangladeshi plants and 08 Thailand plants were found active among 
all tested plant extracts. We selected two Bangladeshi medicinal plants (KKB186: Datura 
stramonium and KKB255: Xanthium strumarium) and one Thailand medicinal plant (KKP87: 
Boesenbergia pandurata) for further bioassay guided separation. The name of all tested plant 
samples are shown in Table 3-1. The activity charts are given below: 
 
 
 
                          Fig. 3-1: TRAIL-resistance overcoming activity of KKB plants 
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                            Fig. 3-2: TRAIL-resistance overcoming activity of KKB plants 
 
 
 
 
                          Fig. 3-3: TRAIL-resistance overcoming activity of KKB plants 
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                          Fig. 3-4: TRAIL-resistance overcoming activity of KKB plants 
 
 
 
 
                          Fig. 3-5: TRAIL-resistance overcoming activity of KKB plants 
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                          Fig. 3-6: TRAIL-resistance overcoming activity of KKB plants 
 
 
 
 
                          Fig. 3-7: TRAIL-resistance overcoming activity of KKB plants 
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                          Fig. 3-8: TRAIL-resistance overcoming activity of KKB plants 
 
 
 
 
                          Fig. 3-9: TRAIL-resistance overcoming activity of KKB plants 
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                          Fig. 3-10: TRAIL-resistance overcoming activity of KKB plants 
 
 
 
 
                          Fig. 3-11: TRAIL-resistance overcoming activity of KKP plants 
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Table 3-1: Name of KKB (Bangladesh) Plants: 
SR
NO. 
KKB 
NO. 
Scientific Name & 
Family 
Plants 
Part 
Sample 
(µg/mL) 
Viability (%) Difference 
(%) Sample Sample + 
TRAIL 
1 16 Terminalia bellirica 
(Combretaceae) 
Fruits 10 
100 
100.3 
7.9 
88.2 
7.3 
12.0 
0.6 
2 105 Alostonia  scholaris  
( Apocyanaceae) 
Bark 10 
100 
99.7 
87.2 
87.5 
18.9 
12.2 
68.3 
3 153 Polygonum lanatum 
(Polygonaceae) 
Leaves 10 
100 
103.7 
39.1 
79.8 
10.5 
23.9 
28.7 
4 156 Gendarussa vulgaris 
(Acanthaceae) 
Leaves 10 
100 
89.4 
88.3 
80.2 
75.0 
9.3 
13.3 
5 162 Calotropis  procera 
(Asclapiadaceae) 
Stem 10 
100 
64.8 
16.4 
28.1 
9.2 
36.7 
7.2 
6 174 Ipomoea mauritiana 
(Convolvulaceae) 
Stem 10 
100 
95.1 
43.6 
81.7 
32.1 
13.5 
11.6 
7 186 Datura stramonium 
(Solanaceae) 
Leaves 10 
100 
54.9 
11.0 
13.7 
10.8 
41.2 
0.3 
8 187 Cyperus rotundus 
(Cyperaceae) 
Leaves 10 
100 
106.7 
84.9 
90.8 
74.7 
15.9 
10.2 
9 201 Hyptis suaveolens 
(Lamiaceae) 
Flowers 10 
100 
96.4 
10.9 
43.1 
9.8 
53.4 
1.1 
10 204 Solanum nigrum  
(Solanaceae) 
Leaves 20 
100 
70.0 
4.1 
4.3 
2.4 
65.7 
1.7 
11 234 Ocimum americanum 
(Lamiaceae) 
Leaves 20 
100 
103.5 
98.9 
94.5 
86.7 
9.0 
12.2 
12 235 Ocimum americanum 
(Lamiaceae) 
Stem 20 
100 
105.2 
94.1 
87.7 
69.7 
17.5 
24.4 
13 236 Ficus racemosus  
(Moraceae) 
Fruits 20 
100 
106.7 
88.8 
94.3 
84.2 
12.3 
4.6 
14 237 Mimosa diplotricha 
 (Fabaceae) 
Whole 
plant 
20 
100 
78.1 
52.9 
53.8 
14.2 
24.2 
38.7 
15 239 Andrographis paniculata 
(Acanthaceae) 
Whole 
plant 
20 
100 
97.3 
18.0 
67.7 
3.4 
29.5 
14.5 
16 241 Bombax ceiba 
(Malvaceae) 
Root 20 
100 
92.9 
87.2 
91.7 
75.5 
1.2 
11.7 
17 242 Glycosmis pentaphylla 
(Rutaceae) 
Leaves 20 
100 
91.6 
93.7 
84.5 
76.4 
7.1 
17.4 
18 243 Glycosmis pentaphylla 
(Rutaceae) 
Root 20 
100 
88.5 
55.1 
86.0 
54.2 
2.5 
1.0 
19 244 Brassica juncea  
(Cruciferae) 
Leaves 20 
100 
100.2 
96.3 
92.5 
92.7 
7.7 
3.5 
20 245 Geodorum densiflorum 
(Orchidaceae) 
Tuber 20 
100 
76.7 
48.2 
73.3 
19.0 
3.5 
29.2 
21 246 Glycosmis pentaphylla 
(Rutaceae) 
Stem 20 
100 
94.6 
105.5 
93.5 
91.5 
1.1 
13.9 
22 247 Lucas aspera  
(Lamiaceae) 
Fruit 20 
100 
86.4 
5.7 
82.9 
3.2 
3.5 
2.4 
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23 249 Achyranthes aspera 
(Amaranthaceae) 
Root 20 
100 
93.9 
93.3 
86.4 
89.7 
7.5 
3.6 
24 250 Ficus hispida  
(Moraceae) 
Stem 20 
100 
57.5 
29.8 
55.7 
19.7 
1.9 
10.1 
25 251 Ficus hispida  
(Moraceae) 
Leaves 20 
100 
47.0 
23.3 
24.7 
2.8 
22.3 
20.5 
26 252 Ricinus communis 
(Euphorbiaceae) 
Stem 20 
100 
105.9 
107.1 
92.7 
85.4 
13.2 
21.7 
27 254 Xanthium strumarium  
(Asteraceae) 
Stem 20 
100 
104.2 
71.1 
88.1 
33.5 
16.1 
37.6 
28 255 Xanthium strumarium  
(Asteraceae) 
Leaves 20 
100 
45.7 
2.5 
7.1 
2.3 
38.6 
0.2 
29 256 Leea macrophylla 
(Vitaceae) 
Stem 20 
100 
111.9 
105.1 
97.5 
87.5 
14.4 
17.7 
30 257 Leea macrophylla 
(Vitaceae) 
Leaves 20 
100 
99.3 
17.7 
96.1 
16.5 
3.2 
1.2 
31 259 Madhuca longifolia 
(Sapotaceae) 
Leaves 20 
100 
103.6 
40.0 
102.5 
37.9 
1.0 
2.1 
32 260 Aphelandra dolichantha 
 (Acanthaceae) 
Leaves 20 
100 
100.1 
101.5 
86.9 
89.9 
13.2 
11.5 
33 261 Aphelandra dolichantha 
 (Acanthaceae) 
Stem 20 
100 
102.8 
82.1 
83.8 
76.5 
19.0 
5.6 
34 262 Solanum surattense 
 (Solanaceae) 
Fruits 20 
100 
90.0 
76.8 
76.3 
68.2 
13.6 
8.6 
35 263 Solanum surattense 
 (Solanaceae) 
Leaves 20 
100 
83.7 
65.1 
69.8 
56.9 
13.9 
8.2 
36 264 Phyllanthus reticulatus 
 (Phyllanthaceae) 
Stem 20 
100 
74.3 
19.4 
74.0 
15.5 
0.3 
4.0 
37 265 Odina wodier  
(Anacardiaceae) 
Bark 20 
100 
81.6 
3.7 
47.2 
3.6 
34.4 
0.1 
38 266 Sansevieria trifasciata  
(Asparagaceae) 
Whole 
plant 
20 
100 
87.8 
65.9 
70.9 
40.4 
16.9 
25.5 
39 269 Acacia mangium  
(Fabaceae) 
Leaves 20 
100 
99.2 
5.0 
87.2 
4.9 
12.0 
0.1 
40 271 Jasminum spp.  
(Oleaceae) 
Aerial 
Parts 
20 
100 
103.4 
12.5 
84.0 
8.9 
19.4 
3.6 
41 272 Randia spp  
(Rubiaceae) 
Aerial 
Parts 
20 
100 
112.1 
70.5 
99.4 
64.6 
12.6 
6.0 
42 273 Flacourtia spp.  
(Flacourtiaceae) 
Aerial 
Parts 
20 
100 
106.4 
73.9 
92.5 
68.2 
13.9 
5.7 
43 274 Syzygium cumini  
(Myrtaceae) 
Leaves 20 
100 
101.1 
44.8 
95.9 
28.4 
5.2 
16.4 
44 275 Suregada multiflora  
(Euphorbiaceae) 
Aerial 
Parts 
20 
100 
63.7 
3.1 
39.2 
2.9 
24.5 
0.2 
45 278 Croton spp.  
(Euphorbiaceae) 
Leaves 20 
100 
89.8 
36.8 
81.3 
28.5 
8.5 
8.3 
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46 279 Semecarpus anacardium  
(Anacardiaceae) 
Leaves 20 
100 
108.1 
10.5 
101.9 
9.0 
6.2 
1.5 
47 280 Syzygium fruticosum 
 (Myrtaceae) 
Leaves 20 
100 
85.3 
4.1 
82.9 
4.0 
2.4 
0.1 
48 281 Hollarhena spp.  
(Apocyanaceae) 
Leaves 20 
100 
88.7 
3.5 
81.3 
2.9 
7.4 
0.6 
49 282 Mucuna spp.  
(Fabaceae) 
Leaves 20 
100 
95.5 
37.3 
86.7 
35.0 
8.8 
2.3 
50 283 Bridelia spp.  
(Euphorbiaceae) 
Leaves 20 
100 
86.1 
4.2 
66.1 
4.1 
20.0 
0.1 
51 284 Microcos paniculata  
(Malvaceae) 
Aerial 
Parts 
20 
100 
95.7 
6.2 
93.3 
3.9 
2.4 
2.3 
52 285 Terminalia bellirica 
(Combretaceae) 
Leaves 20 
100 
86.0 
8.0 
76.7 
7.2 
9.3 
0.8 
53 286 Dalbergia spp.  
(Fabaceae) 
Aerial 
Parts 
20 
100 
90.1 
72.6 
87.9 
70.8 
2.3 
1.7 
54 295 Evolvulus nummularius 
(Convolvulaceae) 
Aerial 
Parts 
20 
100 
66.0 
43.8 
61.9 
41.2 
4.1 
2.7 
55 296 Leea indica  
(Leeaceae) 
Aerial 
Parts 
20 
100 
91.9 
34.6 
82.2 
25.1 
9.7 
9.5 
56 297 Phyla nudiflora  
(Verbanaceae) 
Aerial 
Parts 
20 
100 
74.8 
60.1 
56.4 
57.7 
18.4 
2.4 
57 298 Hibiscus subdariffa  
(Malvacaea) 
Aerial 
Parts 
20 
100 
93.9 
9.9 
75.8 
4.7 
18.0 
5.2 
58 300 Dipteracanthus prostrates 
(Acanthaceae) 
Aerial 
Parts 
20 
100 
83.6 
47.9 
67.5 
35.8 
16.1 
12.1 
59 301 Murraya exotica  
(Rutaceae) 
Leaves 20 
100 
75.0 
3.4 
47.8 
3.3 
27.2 
0.1 
60 302 Azadirachta excelsa 
(Meliaceae)  
Fruits 20 
100 
78.8 
61.6 
50.3 
41.8 
28.5 
19.7 
61 303 Cuscuta reflexa  
(Convovulaceae) 
Aerial 
Parts 
20 
100 
86.7 
51.9 
67.6 
42.4 
19.1 
9.6 
62 304 Scoparia dulcis 
(Scrophulariaceae) 
Aerial 
Parts 
20 
100 
61.9 
24.9 
7.7 
3.6 
54.1 
21.3 
63 305 Moringa olifera  
(Moringaceae) 
Bark 20 
100 
97.0 
41.9 
83.2 
4.7 
13.7 
37.2 
64 314 Cirsium arvense 
(Asteraceae) 
Aerial 
Parts 
5 
10 
105.9 
114.4 
93.1 
84.4 
12.8 
30.0 
65 315 Barringtonia acutangula 
(Lecythidaceae) 
Leaves 5 
10 
103.5 
109.4 
92.0 
82.5 
11.4 
26.9 
66 316 Vitis quadrangularis 
(Vitaceae) 
Aerial 
Parts 
5 
10 
98.3 
104.3 
79.9 
82.2 
18.4 
22.1 
67 317 Syzygium jambos 
(Myrtaceae) 
Leaves 5 
10 
95.5 
96.7 
93.3 
77.3 
2.1 
19.4 
68 318 Ocimum americanum 
(Lamiaceae) 
Whole 
plant 
5 
10 
95.4 
108.0 
91.6 
84.5 
3.7 
23.5 
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69 319 Mimusops elengi 
(Sapotaceae) 
Leaves 5 
10 
99.5 
89.8 
93.3 
88.1 
6.2 
1.7 
70 320 Mimusops elengi 
(Sapotaceae) 
Fruits 5 
10 
93.2 
93.1 
74.5 
77.6 
18.7 
15.5 
71 322 Achyranthes aspera  
(Amaranthaceae) 
Aerial 
Parts 
20 
100 
78.5 
63.3 
65.7 
53.9 
12.8 
9.4 
72 323 Clerodendrum indicum 
(Verbenaceae) 
Aerial 
Parts 
20 
100 
93.2 
81.8 
78.5 
73.9 
14.7 
7.8 
73 324 Alostonia scholaris  
(Apocyanaceae) 
Leaves 20 
100 
81.6 
39.7 
66.7 
16.4 
14.9 
23.2 
74 325 Alternanthera sessilis  
(Amaranthaceae) 
Aerial 
Parts 
20 
100 
93.0 
66.3 
82.2 
64.2 
10.8 
2.2 
75 326 Flacourtia indica  
(Salicaceae) 
Leaves 20 
100 
91.6 
82.5 
76.1 
73.6 
15.5 
8.9 
76 327 Acorus calamus  
(Acoraceae) 
Aerial 
Parts 
20 
100 
57.9 
44.4 
43.6 
39.8 
14.3 
4.5 
77 328 Calophyllum inophyllum 
(Calophyllaceae) 
Leaves 5 
10 
110.1 
115.2 
101.5 
95.5 
8.6 
19.7 
78 329 Glycosmis pentaphylla 
(Rutaceae) 
Leaves 5 
10 
102.8 
106.1 
96.7 
94.1 
6.1 
12.0 
79 330 Artocarpus lacucha 
(Moraceae) 
Leaves 5 
10 
104.8 
110.5 
94.0 
79.8 
10.8 
30.7 
80 331 Streblus asper 
(Moraceae) 
Leaves 5 
10 
93.7 
92.1 
76.3 
74.3 
17.4 
17.8 
81 332 Spondias pinnata 
(Anacardiaceae) 
Fruits 5 
10 
98.4 
102.9 
82.4 
79.0 
15.9 
23.9 
82 335 Sonneratia apetala  
(Sonneratiaceae) 
Fruits 20 
100 
99.3 
97.5 
88.2 
96.9 
11.1 
0.6 
83 336 Thunburgia grandiflora 
(Acanthaceae)  
Stem 20 
100 
115.6 
93.6 
84.2 
70.6 
31.4 
23.0 
84 337 Typha elephantina  
(Typhaceae) 
Root 20 
100 
105.7 
94.0 
89.1 
91.6 
16.6 
2.4 
85 338 Aegiceras corniculatum 
 (Myrsinaceae) 
Fruits 20 
100 
79.7 
9.2 
43.4 
8.0 
36.3 
1.2 
86 339 Nypa fruticans  
(Arecaceae) 
Fruits 20 
100 
38.7 
51.7 
16.6 
20.0 
22.1 
31.7 
87 340 Porteresia coarctata 
(Poaceae)  
Whole 
plant 
20 
100 
85.6 
50.6 
80.9 
31.9 
4.6 
18.8 
88 343 Scindapsus aureus  
(Araceae) 
Aerial 
Parts 
20 
100 
73.4 
75.4 
55.8 
54.3 
17.6 
21.1 
89 345 Syzygium cumini 
(Myrtaceae) 
Bark 4 
20 
95.4 
98.8 
95.4 
86.4 
0 
12.5 
90 346 Litchi chinensis 
(Sapindaceae) 
Leaves 4 
20 
96.1 
103.8 
95.2 
89.4 
0.9 
14.5 
91 347 Litchi chinensis 
(Sapindaceae) 
Bark 4 
20 
95.6 
44.2 
95.5 
25.0 
0.1 
19.2 
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92 350 Annona reticulate 
(Annonaceae) 
Leaves 4 
20 
79.2 
44.8 
71.1 
4.2 
8.1 
40.6 
93 355 Anthocephalus chinensis 
(Rubiaceae) 
Leaves 4 
20 
93.4 
97.6 
92.6 
85.1 
0.8 
12.5 
94 356 Anthocephalus chinensis 
(Rubiaceae) 
Bark 4 
20 
91.1 
97.7 
90.0 
84.7 
1.1 
13.0 
95 357 Aegle marmelos 
(Rutaceae) 
Leaves 4 
20 
99.8 
124.6 
98.7 
92.9 
1.1 
31.7 
96 358 Aegle marmelos 
(Rutaceae) 
Unripe 
Fruits 
4 
20 
102.6 
104.0 
96.6 
88.0 
6.0 
16.0 
97 360 Ficus hispida 
(Moraceae) 
Unripe 
Fruits 
4 
20 
99.4 
93.8 
95.7 
92.1 
3.7 
1.7 
98 363 Terminalia chebula 
(Combretaceae) 
Leaves 4 
20 
97.4 
101.6 
95.6 
98.5 
1.8 
3.1 
99 364 Terminalia chebula 
(Combretaceae) 
Bark 4 
20 
102.7 
94.2 
95.3 
67.2 
7.4 
27.0 
100 365 Terminalia chebula 
(Combretaceae) 
Fruits 4 
20 
104.8 
102.1 
99.7 
90.8 
5.1 
11.3 
101 369 Curcuma zeodaria 
(Zingiberaceae) 
Rhizomes 4 
20 
92.2 
30.3 
83.0 
19.7 
9.2 
10.6 
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Table 3-2: Name of KKP (Thailand) Plants: 
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NO. 
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Plants Part Sample 
(µg/mL) 
Viability (%) Difference 
(%) Sample Sample + 
TRAIL 
1 18 Alstonia scholaris  
(Apocynaceae) 
Leaves 10 
50 
99.2 
98.8 
78.4 
66.1 
20.8 
32.7 
2 80 Millingotonia hortensis  
(Bignoniaceae) 
Leaves & 
Branches 
10 
50 
98.9 
98.9 
77.5 
62.6 
21.4 
36.2 
3 87 Boesenbergia pandurata 
(Zingiberaceae) 
Rhizomes 10 
50 
83.9 
4.9 
29.5 
2.1 
54.4 
2.8 
4 141 Averrhoa bilimbi  
(Oxalidaceae) 
Leaves 10 
50 
86.9 
99.7 
85.8 
87.6 
1.2 
12.1 
5 251 Bryophyllum pinnatum  
(Crassulaceae)  
Leaves 10 
50 
7.7 
3.1 
3.3 
3.0 
4.4 
0.1 
6 267 Dalbergia latifolia  
(Fabaceae) 
Bark 10 
50 
95.4 
28.9 
72.3 
4.6 
23.1 
24.3 
7 268 Dalbergia latifolia  
(Fabaceae) 
Branch 10 
50 
87.6 
96.0 
77.7 
68.7 
9.9 
27.2 
8 270 Dolichos lablab  
(Fabaceae) 
Leaves 10 
50 
98.8 
98.8 
89.9 
72.1 
8.9 
26.7 
9 274 Borassus flabellifer 
(Arecaceae) 
Flowers 10 
50 
99.1 
17.5 
76.4 
16.6 
22.6 
0.8 
10 277 Crotalaria juncea  
(Fabaceae) 
Leaves 10 
50 
99.6 
98.2 
77.5 
71.5 
22.1 
26.6 
11 283 Casuarina equisetifolia 
 (Casuarinaceae) 
Leaves 10 
50 
98.7 
5.9 
97.3 
5.1 
1.3 
0.8 
12 326 Nephelium hypoleucum 
(Spindaceae)  
Bark 10 
50 
66.8 
2.4 
25.8 
2.2 
41.0 
0.2 
13 430 Wrightia religiosa  
(Apocynaceae) 
Leaves 10 
50 
99.5 
98.6 
78.1 
61.8 
21.4 
36.8 
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Chapter 4: Isolation of Datura stramonium 
 
 
Plant description 
Datura stramonium (Solanaceae) is a well known folklore medicinal herb. It is wild growing 
flowerings annul plant. Leaves are generally light dull green, ovate to triangular ovate 4 to 6 
inches long and uneven at the base. Flowers are funnel shaped white or purple color. Fruits are 
full of thorns and hence it is called “thorn apple” in English.1 This plant is probably originated in 
Caspian Sea territories and spreaded to Europe in the first century. Now, it grows in waste 
places in Europe, Asia, America, and South Africa.2 D. stramonium is traditionally used for the 
treatment of asthma, parkinsonism, hemorrhoids, dental pain, alopecia, stomach and intestinal 
pain.1 The leaves of D. stramonium are used for the relief of headache and vapours of leaf 
infusion is used to relive the pain of rheumatism and gout. The fruit juice is applied to the scalp 
for the treatment of falling hair and dandruff.2 The major constituents of D. stramonium is 
tropane alkaloids – atropine, scopolamine, and hyoscyamine. The leaves of D. stramonium were 
collected from Natore, Bangladesh. A voucher specimen KKB186 was preserved in the 
Laboratory of Natural Products Chemistry, Graduate School of Pharmaceutical Sciences, Chiba 
University, Japan. 
                          
                                                        Datura stramonium 
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Extraction and Isolation of Compounds 
The air-dried and grounded of D. stramonium leaves (66 g) were subjected to extraction with 
MeOH for two days at room temperature followed by homogenization and filtration and then 
evaporation and vacuum desiccation overnight to obtain crude extract (5 g, 7.58% w/w). The 
MeOH extract was chromatographed on Diaion HP-20 (φ 5 x 25 cm); particle size (250-850 
mm) using MeOH/Acetone solvent to remove the chlorophyll and afforded four fractions (Three 
methanolic - M1, M2, M3, and acetone-A). The active fraction M2 (1 gm) was subjected to 
silica gel PSQ 100 column chromatography (φ 2.2 x 29 cm) and eluted with CHCl3: MeOH 
solvent system (10:0-0:1, then washed with 1% TFA with MeOH) to afford the fractions 1A-1M. 
1F (270 mg) was subjected to silica gel 60N column chromatography (φ 2.4 x 48 cm) and eluted 
with CHCl3: MeOH solvent system (10:0-0:1, then washed with 1% TFA with MeOH) to afford 
the fractions 7A-7N and compound 1 (8 mg). As fraction M2 was separated much amount, then 
M2 (1.4 gm) again eluted with silica gel PSQ 100 column chromatography (φ 2.7 x 32 cm) using 
CHCl3: MeOH solvent system (10:0-0:1, then washed with 1% TFA with MeOH) to afford the 
fractions 9A-9R and compound 2 (7.4 mg). 9J (241.5 mg) was subjected to silica gel 60N 
column chromatography (φ 2.4 x 30 cm) and eluted with CHCl3: MeOH solvent system (10:0-
0:1, then washed with 1% TFA with MeOH) to afford the fractions 10A-10W. 10P (25 mg) 
again eluted with sephadex LH-20 column chromatography (φ 1.2 x 33 cm) using MeOH 
solvent system to afford the fractions 11A-11G and compound 3 (1.4 mg). 
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7A
3.3
7B
1.7
7C
1.4
7D
8
7E
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63.2
7G
4.9
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8.9
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7.7
1D
6.9
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270.6
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53.3 mg
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9.8
9F
8.7
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8.8
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9I
69
9J
241.5
9K
302
9L
129
9M
112
9N
150
9O
35
9P
94
9Q
7.4
9R
164 
 mg
M1
806 mg
M2
2.57 g
M3
297 mg
A
1.06 g
MeOH Extract of D. stramonium
 
(5.0 g)
MeOH/Acetone Diaion HP-20 CC
CHCl3/MeOH Silica gel PSQ 100
CHCl3/MeOH Silica gel 60N
7M
26.6
7N
70 mg
1 (scopolamine) M2 (1.4 g)
CHCl3/MeOH Silica gel PSQ 100
2 (trigonelline)
Silica gel 60N
Sephadex LH20
3
 
(1.4 mg) 
(tyramine)
1/0 1/0 1/1 0/1
 
 
Fig. 4-1: Isolation scheme of D. stramonium leaves 
 
Structure elucidation of 1-3 
Bioassay guided fractionation of D. stramonium. leaves led to the isolation of three alkaloids – 
scopolamine (1), trigonelline (2), and tyramine (3). The structure of compounds 1-3 were 
determined by comparing with spectral data of known compounds in the literature. 
 
Scopolamine (1)3-6 
C17H21NO4 (MW 303), ESI-MS m/z 304 [M+H]+, [α]D24 _11.4  (c 1.00 CHCl3), 1H and 13C NMR 
data, see Table 4-1. 
 
Red: Active Fraction 
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Trigonelline (2)7-8 
C7H7NO2 (MW 137), ESI-MS m/z 138 [M+H]+, 1H and 13C NMR data, see Table 4-2. 
Tyramine (3)9 
 
C8H11NO (MW 137), ESI-MS m/z 138 [M+H]+, 1H and 13C NMR data, see Table 4-3. 
 
Table 4-1: NMR Spectroscopic data of Compound 1 (scopolamine) 
 
 δH (J in Hz) (1) 
(600 MHz & CDCl3) 
 δC  (1) 
(150 MHz) 
1 2.97 (1H, dd, 1.8, 4.8) 57.8 
2 2.11 (1H, dt, 15, 4.8) & 
1.56 (1H, d, 15) 
30.7 
3 5.00 (1H, d, 4.8) 66.8 
4 2.02 (1H, dt, 15, 4.8) & 
1.33 (1H, d, 15) 
30.9 
5 3.10 (1H, dd, 1.8, 3.6) 57.9 
6 3.35 (1H, d, 3.6) 54.2 
7 2.64 (1H, d, 3.6) 55.8 
8 2.44 (3H, s) 42.2 
9  171.8 
10 3.72 (1H, dd, 5.4, 9) 54.2 
11 3.79 (1H, dd, 5.4, 10.8) & 
4.13 ((1H, dd, 9, 10.8) 
64.0 
12  135.6 
13 7.19 (2H, d, 7.8) 128.0 
14 7.33 (2H, d, 7.8) 129.0 
15 7.29 (1H, d, 7.8) 128.0 
 
 
Table 4-2: NMR Spectroscopic data of Compound 2 (trigonelline) 
 
 δH (J in Hz) (2) 
(600 MHz & DMSO D6) 
 δC  (2) 
(150 MHz) 
1   
2 9.16 (1H, s) 126.6 
3  143.9 
4 8.84 (1H, d, 6) 145.9 
5 7.99 (1H, t, 6) 140.5 
6 8.72 (1H, d, 6) 144.4 
7 4.33 (3H, s) 47.5 
8  161.9 
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Table 4-3: NMR Spectroscopic data of Compound 3 (tyramine) 
 
 δH (J in Hz) (3) 
(600 MHz & CD3OD) 
2 & 6 7.08 (2H, d, 8.4) 
3 & 5 6.76 (2H, d, 8.4) 
7 2.85 (2H, t, 7.5) 
8 3.11 (2H, t, 7.5) 
  
Activity of isolated compounds 1-3 
Previous study reported that compound 1 has acetylcholine esterase and protease inhibitory 
activity and thereby improving Alzheimer’s disease and dementia,10 and compound  1 also 
reduced persistent activity related to long-term encoding in the parahippocampal gyrus during 
delayed matching in human.11 Compound 2 showed antidiabetic activity,12 anti-invasive activity 
against hepatoma cell line (AH109A)13 and 2 also induced neurite outgrowth in human 
neuroblastoma SK-N-SH cells.14  Compound 3 showed vasorelaxant15 and non-specific 
stimulant activity on isolated intestinal preparation.16  
 
Isolated compounds showed TRAIL-resistance overcoming activity 1 at 50 μM (42% difference), 
2 at 150 μM (44% difference) and 3 at 100 μM (32% difference) in TRAIL-resistant AGS cells.  
 
 
  
  
 
 
 
Fig. 4-1: TRAIL-resistance overcoming activity of compounds (1-3), Luteolin (positive control: 
Lut), and DMSO (negative control: Cont.) in the presence and absence of TRAIL in TRAIL-
resistant AGS cells. Cells were seeded in a 96-well culture plate (6 x 103 cells per well) for 24 h 
and then treated with indicated concentration of the compounds and TRAIL (100 ng/mL) for 24 
h. Viability was evaluated by the FMCA method. Data represent the means ± SD (n = 4).  
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Chapter 5: Isolation of Xanthium strumarium 
 
 
Plant description 
Xanthium strumarium (Asteraceae) is an annual herb with potential medicinal properties. The 
stem of the plant is erect, rough-hairy, usually branched with purple spots. Flowers are small, 
unisexual, and green in color. Flowering occurs during August-September and seed mature from 
August to October. Fruits are hard, woody, and covered with spines.1 It is distributed in North 
America, Brazil, China, Malaysia, and India. Traditionally the plant is used for the treatment of 
malarial fever, cough, asthma, diarrhea, eczema, rheumatoid arthritis, migraine, and small pox.1 
The polyphenols, 3,5-di-O-caffeoylquinic acid and 1,3,5-tri-O-caffeoylquinic acid have been 
isolated from fruits.2 The aerial parts of X. strumarium yielded xanthumin, xanthanol, 
isoxanthanol, tomentosin, 8-epi-xanthatin, 2-hydroxytomentosin, and 2-hydroxytomentosin-
1β,5β-epoxide.3 The leaves of X. strumarium were collected from Natore, Bangladesh. A 
voucher specimen KKB255 was preserved in the Laboratory of Natural Products Chemistry, 
Graduate School of Pharmaceutical Sciences, Chiba University, Japan. 
 
                             
                                                      Xanthium strumarium 
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Extraction and Isolation of Compounds 
The air-dried and grounded leaves of Xanthium strumarium (108 g) were subjected to extraction 
with MeOH for two days at room temperature followed by homogenization and filtration, and 
then evaporation and vacuum desiccation overnight to obtain a crude extract (21 g). The extract 
was chromatographed on Diaion HP-20 (φ 7 x 28 cm); particle size (250-850 mm) to remove the 
chlorophyll and afforded four fractions 1A to 1D. The chlorophyll-free active fraction 1A (14.4 
g) was suspended in 10% aqueous MeOH (300 ml) and partitioned between n-hexane, EtOAc, 
and n-BuOH (300 ml x 3) to obtain n-hexane 2A (5.8 g), EtOAc 2B (2.3 g), n-BuOH 2C (3 g), 
and water 2D (3.1 g) soluble fractions. The n-hexane soluble active fraction 2A (5 g) was 
subjected to silica gel 60N column chromatography (φ 6 x 30 cm) and eluted with a CHCl3: 
MeOH solvent system (10:0 – 0:1, then washed with 1% TFA in MeOH) to afford the fractions 
3A to 3M. Fraction 3J (650 mg) was subjected to silica gel 60N column chromatography (φ 3.4 
x 29 cm) and eluted with a CHCl3: MeOH solvent system (10:0 – 0:1, then washed with 1% 
TFA in MeOH) to afford the fractions 4A to 4F. Fraction 4E (77 mg) eluted with 75% MeOH 
using preparative ODS HPLC column chromatography [Cosmosil (5C18 – AR-II), φ 10ID x 250 
mm, flow rate: 2 mL/min, RI and UV detection at 254 nm] to afford compound 4 (22 mg, tR 10 
min). Fraction 3K (90 mg) was subjected to preparative ODS HPLC column chromatography 
[Cosmosil (5C18 – AR-II), φ 10ID x 250 mm, flow rate: 2 mL/min, RI and UV detection at 254 
nm] using 60% MeOH to afford compound 4 (12 mg, tR 16 min) and compound 5 (1.6 mg, tR 15 
min). As fraction 3K was separated much amount, then 3K (1.77 g) again eluted with ODS 
column chromatography  (φ 4.4 x 28 cm) using MeCN: H2O solvent system (3:7 – 10:0, then 
washed with 1% TFA in MeCN) to afford fractions 13A to 13N and compound 4 (469 mg). 
Fraction 13J (101 mg) was purified by preparative reverse-phase HPLC column chromatography 
[Cosmosil Cholester, φ 10ID x 250 mm, flow rate: 2 mL/min, RI and UV detection at 254 nm] 
using 90% MeOH to afford compound 8 (18.5 mg, tR 20 min). The EtOAc soluble active 
fraction 2B (2 g) was subjected to silica gel 60N column chromatography (φ 2.6 x 31 cm) and 
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eluted with a CHCl3: MeOH solvent system (10:0 – 0:1, then washed with 1% TFA in MeOH) 
to afford the fractions 11A to 11Z. Fraction 11I (70 mg) was subjected to preparative reverse-
phase HPLC column chromatography [Cosmosil Cholester, φ 10ID x 250 mm, flow rate: 2 
mL/min, RI and UV detection at 254 nm] using 60% MeOH to afford compound 4 (15mg, tR 17 
min), compound 5 (2 mg, tR 15 min), compound 6 (2.8 mg, tR 19 min), and compound 7 (1.4 mg, 
tR 21 min).  
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Fig. 5-1: Isolation scheme of X. strumarium leaves 
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Structure elucidation of 4-8 
Bioassay guided fractionation of X. strumarium leaves led to the isolation of five sesquiterpene 
lactones – xanthinosin (4),4 11α,13-dihydroxanthinin (5),  4α,11α,13-trihydroxanthuminol (6),  
desacetylxanthanol (7),5  and lasidiol p-methoxybenzoate (8)6. The structure of compounds 4, 7, 
and 8 were determined by comparing with spectral data of known compounds in the literature. 
Compounds 5 and 6 were first isolated from natural resources. Previous study reported the 
semisynthetic unseparable diastereomeric mixture of compound 5 and 6 at position 4 and 11.  
 
Xanthinosin (4)4 
C15H20O3 (MW 248), ESIMS m/z [M+H]+ 249, [α]D24 - 37.9 (c 0.44, CHCl3), 1H and 13C NMR 
data, see Table 5-1. 
 
11α,13-dihydroxanthinin (5) 
C15H22O3 (MW 250), HRESIMS m/z [M+Na]+ 273.1487 (Δ + 2.0 mmu) calculated as 273.1467,  
[α]26D  - 42.0 (c 0.3, CHCl3),  1H and 13C NMR and 2D NMR data, see Table 5-2. 
 
4α,11α,13-trihydroxanthuminol (6) 
C15H24O3 (MW 252), HRESIMS m/z [M+Na]+ 275.1623 (Δ ± 0.0 mmu) calculated as 275.1623), 
[α]26D  - 30.0 (c 0.36, CHCl3),  1H and 13C NMR and 2D NMR data, see Table 5-3. 
 
Desacetylxanthanol (7)5  
C15H22O3 (MW 250), ESIMS m/z [M+H]+ 251, [α]D24 -23.7 (c 0.33, CHCl3), 1H and 13C NMR 
data, see Table 5-5. 
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Lasidiol p-methoxybenzoate (8)6 
C23H32O4 (MW 372), ESIMS m/z [M+Na]+ 395, [α]D24 -173.6 (c 0.8, CHCl3), 1H and 13C NMR 
data, see Table 5-6. 
 
Table 5-1: NMR Spectroscopic data of Compound 4 (xanthinosin) 
 
 δH (J in Hz) (4) 
(600 MHz & CDCl3) 
 δC  (4) 
(150 MHz) 
1  146.2 
2 2.24 (1H, m) & 2.27 (1H, m) 34.4 
3 2.50 (2H, m) 42.7 
4  208.0 
5 5.49 (1H, d, 9) 121.6 
6 2.45 (1H, m) & 1.97 (1H, m) 25.9 
7 2.47 (1H, m) 48.1 
8 4.21 (1H, ddd, 12, 10.2, 3) 82.0 
9 2.22 (1H, m) & 
1.72 (1H, td, 12, 4.2) 
37.0 
10 2.45 (1H, m) 34.0 
11  139.7 
12  170.1 
13 6.10 (1H, d, 3) & 
5.39 (1H, d, 3) 
118.4 
14 1.09 (3H, d, 7.2) 18.4 
15 2.11 (3H, s) 30.0 
 
Compound 5 was isolated as optically active colorless amorphous solid, with molecular formula 
assigned as C15H22O3. Previous study reported the semisynthetic unseparable diastereomeric 
mixture at position C-11.7 Compound 5 is a trans-fused β-methyl substituted lactone ring with β-
methyl substituted seven membered ring containing sesquiterpene lactone. The 1H NMR 
spectrum (Table 5-2) of 5 exhibited three sp3 methyls [δH 1.16 (3H, d, J = 7.2 Hz), 1.10 (3H, d, J 
= 7.2 Hz), and 2.13 (3H, s)], four sp3 methylene [δH 2.24 (2H, m), 2.50 (2H, m), 2.09 (1H, m), 
and 2.00 (1H, m) and 2.24 (1H, m) and 1.62 (1H, m)], four sp3 methine [δH  2.00 (1H, m), 4.47 
(1H, ddd, J = 12.6, 9.0, 3.0 Hz), 2.43 (1H, m), and 2.62 (1H, m)] and one sp2 methine [δH  5.45 
(1H, d, J = 10.2 Hz)]. The 13C NMR spectrum (Table 5-2) of 5 showed 15 carbons, comprising 
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two carbonyl carbons (δC 208.1 and 179.6), three sp3 methyls (δC 10.1, 18.0, and 30.0), four sp3 
methylenes (δC 34.5, 42.6, 24.3, and 36.8), four sp3 methines (δC 46.7, 81.4, 34.1, and 40.0), one 
sp2 methine carbon (δC 122.4), and one sp2 quaternary carbon (δC 146.0). Previous studies 
reported the same chemical skeleton of 5 but have different stereochemistry at position C-8 and 
C-11.8,9 Comparison of 1H NMR of 5 with reported compound data showed that position H-2, 
H-3, H-6, H-7, H-9, and H-11 are different from reported compound and also 13C NMR data at 
C-1, C-2, C-5, C-6, C-7, C-8, C-9, C-10, C-11, C-13, and C-14 are different from reported 
compound. The structure of 5 was determined by 1H and 13C NMR and 1H-1H COSY, HMQC, 
and HMBC and the relative stereochemistry was determined by difference NOE correlations. 
Position H-8, H-13, and H-14 showed good NOE correlations and compatible with the structure 
5 (11α,13-dihydroxanthinin) (Fig. 5-3). 
 
                 
O
O
H
H
146.0
2.24 (m)
34.5
3
208.1
5
6
7
8
9
10
14
11
12
13
15
2.50 (m)
42.6
2.13 (s)
30.0
2 1
1.10 (d, 7.2)
18.0
5.45 (d, 10.2)
122.4
2.09 (m) 
2.00 (m)
24.3
46.7
2.00 (m)
81.4
4.47 
(ddd, 12.6, 9, 3)
1.16 (d, 7.2)
10.1
2.43 (m)
34.1
2.24 (m) 
1.62 (m)
36.8
2.62 (m)
40.0
4
179.6
O
 
                                           Fig. 5-2: 1H and 13C NMR of 5 
 
1H NMR 600 MHz, CDCl3 
13C NMR 150 MHz, CDCl3 
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 Fig. 5-3: COSY (Bold line), Key HMBC (arrows) and NOE correlations of 5 
 
Table 5-2: 1H NMR, 13C NMR, and 2D NMR data of 5 in CDCl3 (600 MHz) 
Position δH (J in Hz) (5) 
(600 MHz & CDCl3) 
δC (5) 1H-1H COSY HMBC 
1  146.0   
2 2.24 (2H, m) 34.5 2.50 34.1, 42.6, 122.4, 146.0 
3 2.50 (2H, m) 42.6 2.24 34.5, 146.0, 208.1 
4  208.1   
5 5.45 (1H, d, 10.2)  122.4 2.00, 2.09   34.5, 24.3, 46.7 
6 2.09 (1H, m)  
2.00 (1H, m) 
24.3 5.45, 2.00  
5.45, 2.09 
40.0, 46.7, 81.4, 122.4,  
146.0,  81.4 
7 2.00 (1H, m) 46.7 4.47, 2.62, 2.09 10.1, 81.4 
8 4.47 (H, ddd, 12.6, 9.0, 3.0) 81.4 1.62, 2.00, 2.24  
9 2.24 (1H, m)  
1.62 (1H, m) 
36.8 4.47, 1.62, 2.43  
4.47, 2.24, 2.43 
34.1, 46.7, 81.4, 146.0  
18.0, 34.1, 46.7, 81.4 
10 2.43 (1H, m) 34.1 1.10, 1.62, 2.24 122.4, 146.0 
11 2.62 (1H, m) 40.0 1.16, 2.00  10.1, 81.4 
12  179.6   
13 1.16 (3H, d, 7.2) 10.1 2.62 40.0, 46.7, 179.6 
14 1.10 (3H, d, 7.2) 18.0 2.43 34.1, 36.8, 146.0 
15 2.13 (3H, s) 30.0  42.6, 208.1 
 
Compound 6 was isolated as optically active colorless amorphous solid, with molecular formula 
assigned as C15H24O3. Previous study reported the semisynthetic unseparable diastereomeric 
mixture of 6 at position C-4 and C-11.7 The 1H and 13C NMR spectral data (Table 5-3) of 6 
revealed the presence of trans-fused β-methyl substituted lactone ring [δH 1.17 (3H, d, J = 7.7 
COSY
Key HMBC  
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Hz), 2.62 (1H, quint, J = 7.7 Hz), 2.01 (1H, m), 4.49 (1H, ddd, J = 13.2, 9.6, 3.6 Hz); δC 179.6, 
81.6, 46.7, 40.0, 10.1] condensed with a β-methyl-substituted seven-membered ring [δH  5.49 
(1H, d, J = 9.6 Hz), 2.14 and 2.01 (2H, m), 2.01 (1H, m), 4.49 (1H, ddd, J = 13.2, 9.6, 3.6 Hz), 
1.60 and 2.23 (2H, m), 2.48 (1H, m), 1.11 (3H, d, J = 7.8 Hz); δC 147.1, 122.0, 24.3, 46.7, 81.6, 
37.0, 33.8, 18.1]. Additionally, a four carbon atoms containing side chain was assigned by the 
signals at δH 2.14 and 2.23 (2H, m), 1.60 (2H, m), 3.79 (1H, m), and 1.19 (3H, d, J = 6.0 Hz) and 
δC 38.0, 38.0, 68.0, and 23.5 ppm. The 1H-1H COSY, HMQC, and HMBC spectra led to the 
identification of three sp3 methyl, four sp3 methylene, five sp3 methine, one sp2 methine, one sp2 
quaternary carbon, and one carbonyl carbon atom in the compound 6. The difference NOE 
correlations between H-8, H-13, and H-14 showed that β-methyl substituted trans lactone ring 
fused with β-oriented 14-methyl group containing seven membered ring in compound 6 (Fig. 5-
4). The chemical skeleton of compound 6 was similar to 2-desacetoxy-11α,13-
dihydroxanthuminol and 11β,13-dihydro-4H-tomentosin but different stereochemistry at H-8 
and H-11.10,11 The absolute stereochemistry of compound 6 at C-4 was determined by modified 
Moshers’ method (Fig. 5-6).12 So the compound 6 is 4α,11α,13-trihydroxanthuminol. 
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                                              Fig. 5-4: 1H and 13C NMR of 6 
1H NMR 600 MHz, CDCl3 
13C NMR 150 MHz, CDCl3 
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Fig. 5-5: COSY (Bold line), Key HMBC (arrows) and NOE correlations of 6 
 
Table 5-3: 1H NMR and 13C NMR and 2D NMR data of 6 in CDCl3 (600 MHz) 
 
Position δH (J in Hz) (6) 
(600 MHz & CDCl3) 
δC (6) 
(150 MHz) 
1H-1H COSY HMBC 
1  147.1   
2 2.14 (1H, m) 
2.23 (1H, m) 
38.0  
1.60 
33.8, 38.0, 122.0, 147.1 
3 1.60 (2H, m) 38.0 3.79, 2.23  
4 3.79 (1H, m) 68.0 1.19, 1.60  
5 5.49 (1H, br d, 9.6) 122.0 2.14 24.3, 33.8, 38.0, 46.8 
6 2.14 (1H, m) 
2.01 (1H, m) 
24.3 5.49, 2.01 81.6, 122.0, 147.1, 
122.0 
7 2.01 (1H, m) 46.8 4.49, 2.14 122.0 
8 4.49 (1H, ddd, 13.2, 9.6, 3.6) 81.6 2.23, 2.01, 1.60  
9 1.60 (1H, m) 
2.23 (1H, m) 
37.0 4.49, 2.23, 
1.60 
18.1 
10 2.48 (1H, m) 33.8 1.11  
11 2.62 (1H, quint, 7.7) 40.0 1.17, 2.01 10.1, 81.6 
12  179.6   
13 1.17 (3H, d, 7.7) 10.1 2.62 46.8, 179.6 
14 1.11 (3H, d, 7.8) 18.1 2.48 33.8, 37.0, 147.1 
15 1.19 (3H, d, 6) 23.5 3.79 38.0, 68.0 
 
Absolute stereochemistry of 6 at C-4 by modified Moshers’ method: 
The absolute configuration of 6 at C-4 was determination by modified Moshers’ method.12 
Compound 6 was reacted separately with both S-MTPA-Cl and R-MTPA-Cl. After the reaction 
with 6, the S-MTPA-Cl converted to R-MTPA ester of 6 and the R-MTPA-Cl converted to S-
COSY
Key HMBC  
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MTPA ester of 6 and measured the 1H NMR and then compare the chemical shift of both R-
MTPA ester and S-MTPA ester. Generally ester has higher Rf value than the compound 6. 
 
Reaction Protocol 
1. A screw cap was fitted with a small round glass flask and taken a Teflon coated magnetic 
stir bar. 
2. Compound 6 (0.5 mg) was dissolved in dry pyridine. 
3. R-(-)-MTPA-Cl (3 mg) was added to the mixture. This transfer was performed using a 
microliter syringe. 
4. The reaction mixture were stirred overnight (12 h) and then checked TLC  
5. After the reaction, the mixtures were separated by EtOAc and water solvent fractionation 
6. Then 1H NMR was checked   
7. After reaction, R-(-)-MTPA-Cl formed the S-(+)-MTPA ester of 6. 
8. Same procedure was done for the preparation of R-(-)-MTPA ester of 6 from S-(+)-
MTPA-Cl. 
 
Table 5-4: Chemical Shift of S-MTPA-ester and R-MTPA-ester of 6 (CDCl3): 
 
 1H NMR (S-MTPA ester of 6) 
(600 MHz), δS 
1H NMR (R-MTPA ester of 6) 
 (600 MHz), δR 
Δδ = δS - δR 
(ppm) 
Δδ = δS - δR 
(MHz) 
1     
2 2.177 
2.246 
2.187 
2.253 
- 0.01 
- 0.007 
- 6 
- 4.2 
3 1.491 1.496 - 0.005 - 3 
4 3.730 3.765 - 0.035 - 21 
5 5.388 5.379 + 0.009 + 5.4 
6 2.177 
1.987 
2.187 
1.991 
- 0.01 
- 0.004 
- 6 
- 2.4 
7 1.987 1.991 - 0.004 - 2.4 
8 4.371 4.380 - 0.009 - 5.4 
9 2.172 
1.689 
2.185 
1.694 
- 0.013 
- 0.005 
-7.8 
-3 
10 2.346 2.352 - 0.006 - 3.6 
11 2.551 2.549 + 0.002 + 1.2 
12     
13 1.114 1.102 + 0.012 + 7.2 
14 1.055 1.055 0 0 
15 1.220 1.210 + 0.01 + 6 
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The absolute stereochemistry of 6 at C-4 is R-hydroxyl. 
 
Fig. 5-6: Absolute stereochemistry of 6 at C-4 by modified Moshers’ method 
 
 
Table 5-5: NMR Spectroscopic data of Compound 7 (desacetylxanthanol) 
 
 δH (J in Hz) (7) 
(600 MHz & CDCl3) 
 δC  (7) 
(150 MHz) 
1  146.2 
2 2.27 (2H, m) 34.4 
3 2.50 (2H, m) 38.1 
4 3.79 (1H, m) 68.0 
5 5.56 (1H, dd, 3, 8.4) 121.4 
6 2.02 (2H, m) 25.9 
7 2.55 (1H, m) 48.3 
8 4.25 (1H, ddd, 13.2, 9.6, 3) 82.2 
9 2.14 (2H, m) 37.0 
10 2.50 (1H, m) 33.8 
11  139.8 
12  165.4 
13 6.13 (1H, d, 3) & 
5.41 (1H, d, 3) 
118.5 
14 1.12 (3H, d, 7.8) 18.5 
15 1.20 (3H, d, 6) 23.7 
 
 
 
7 (desacetylxanthanol) 
 
When, Δδ = δS – δR, proton on the right side of 
the MTPA plane must have positive values 
(Δδ ˃ 0) and protons on the left hand side must 
have negative values (Δδ ˂ 0). The absolute 
values of Δδ must be proportional to the 
distance from the MTPA moiety.12  
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Table 5-6: NMR Spectroscopic data of Compound 8 (lasidiol p-methoxybenzoate) 
 
 δH (J in Hz) (8) 
(600 MHz & CDCl3) 
δC  (8) 
(150 MHz) 
1 5.29 (1H, d, 6) 77.9 
2 5.48 (1H, d, 6) 121.7 
3  143.0 
4 2.27 (2H, m) 30.2 
5 2.02 (2H, m) 35.5 
6  83.3 
7  53.5 
8 1.50 (1H, m) & 
1.59 (1H, m) 
24.8 
9 1.42 (1H, m) & 
1.69 (1H, m) 
36.0 
10 1.69 (1H, m) 56.8 
11 1.85 (1H, m) 26.6 
12 0.94 (3H, d, 6.6) 21.3 
13 1.02 (3H, d, 6.6) 24.5 
14 1.04 (3H, s) 22.8 
15 1.67 (3H, s) 25.7 
16  165.9 
17  123.1 
18 & 22 7.97 (2H, d, 9) 131.5 
19 & 21 6.91 (2H, d, 9) 113.6 
20  163.3 
23 3.84 (3H, s) 55.4 
 
Activity of isolated compounds 4-8 
Previous studies reported that compound 4 showed cytotoxicity in WiDr (human colon cancer) 
cells and MDA-MB-231 (human breast cancer) cells,4 inhibition of nitric oxide (NO) production 
in LPS-activated microglial BV-2 cells,13 anti-ulcerogenic activity,14 anti-fungal and 
leishmanicidal activity,15 and compound 8 showed leishmanicidal activity.16 
 
All compounds showed potent TRAIL-resistance overcoming activity, such as, 4 at 8 μM (44% 
difference), 5 at 20 μM (61% difference), 6 at 20 μM (51% difference), 7 at 16 μM (48% 
difference), and 8 at 16 μM (61% difference) in TRAIL-resistant AGS cells (Fig. 5-7).  
 
 
HO
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8 (lasidiol p-methoxybenzoate) 
 
44 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Fig 5-7: TRAIL-resistance overcoming activity of compounds (4-8), Luteolin (positive control: 
Lut), and DMSO (negative control: Cont.) in the presence and absence of TRAIL on the 
viability of AGS cells. AGS cells were seeded in a 96-well culture plate (6 x 103 cells per well) 
for 24 h and then treated with indicated concentration of the compounds and TRAIL (100 
ng/mL) for 24 h. Viability was evaluated by the FMCA method. Data represent the means ± SD 
(n = 4). 
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Activity of compound 4 in other cell lines 
Compound 4 showed TRAIL-resistance overcoming activity in HeLa (cervical cancer) cells at 
12 µM (42% difference), DLD1 (colorectal cancer) cells at 12 µM (38% difference), DU145 
(prostate cancer) cells at 8 µM (33% difference), and MCF7 (breast cancer) cells at 12 µM (31% 
difference). However, compound 4 did not decrease viability in non-cancer (HEK293) cells up 
to 8 µM (Fig. 5-8). 
            
 
              
 
Fig 5-8: Effects of compound 4, Luteolin (positive control: Lut), and DMSO (negative control: 
Cont.) in the presence and absence of TRAIL. Cells were seeded in a 96-well culture plate (6 x 
103 cells per well) for 24 h and then treated with indicated concentration of the compound 4 and 
TRAIL (100 ng/mL) for 24 h. on HeLa cells, DLD1 cells, DU145 cells, MCF7 cells, and 
HEK293 cells. Viability was evaluated by the FMCA method. Data represent the means ± SD (n 
= 4). 
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Chapter 6: Isolation of Boesenbergia pandurata 
 
 
Plant description 
Boesenbergia pandurata (Zingiberaceae) is a culinary herb found in South-East Asia and China. 
The plant has many synonymously botanical names, such as, Gastrochilus panduratum, 
Kaempferia pandurata, Curcuma rotunda, and Boesenbergia rotunda. The plant has different 
local name, such as, “temu kunci” (Indonesia), “krachai” (Thailand), and “Fingerroot” (English). 
According to the Indonesian medicinal plants literatures, fresh rhizome of B. pandurata has been  
long time utilized as spice for seasoning vegetables.1 Traditionally the rhizomes is used for the 
treatment of dry cough, stomach ulcers, inflammation in uterus, vaginal infection, and cancer.1 
The rhizome of the plant is one of the components of herbal medicine “jamu” in Indonesia.2 
Several flavonoid chalcones, flavanones, flavones, and pimarane diterpenes were isolated and 
identified from the rhizome extract of B. pandurata.1 The rhizomes of B. pandurata were 
collected from Thailand. A voucher specimen KKP87 was preserved in the Laboratory of 
Natural Products Chemistry, Graduate School of Pharmaceutical Sciences, Chiba University, 
Japan. 
 
    
 
 
 
 
Boesenbergia pandurata Rhizomes 
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Extraction and Isolation of Compounds 
The air-dried and grounded rhizomes of B. pandurata (150 g) were subjected to extraction with 
MeOH for five days at room temperature followed by homogenization and filtration, and then 
evaporation and vacuum desiccation overnight to obtain a crude extract (18.5 g). The extract was 
partitioned between n-hexane, EtOAc, and n-BuOH (400 ml x 3) to obtain n-hexane (10.0 g), 
EtOAc (3.0 g), n-BuOH (2.1 g), and water (2.23 g). The EtOAc fraction (3.0 g) was subjected to 
silica gel 60N column chromatography (φ 5 x 30 cm) and eluted with a hexane: EtOAc solvent 
system (10:0 – 0:1) to afford the fractions 1A to 1T and compound 9 (83 mg). Fraction 1M (133 
mg) eluted with ODS flash column chromatography (φ 1.8 x 25 cm) using MeOH/H2O to afford 
fractions 2A to 2F and compound 10 (25 mg). The fraction 1N (247 g) was subjected to ODS 
flash column chromatography (φ 1.8 x 28 cm) and eluted with a MeOH/H2O solvent system to 
afford the fractions 3A to 3L and compound 10 (25 mg) and 17 (3.8 mg). Fraction 2D (51 mg) 
was eluted with preparative ODS HPLC [YMC Pack Pro C18, (φ 10ID x 250 mm), flow rate: 2 
mL/min, RI and UV detection at 254 nm] using 80% MeOH to afford compound 9 (16 mg), 10 
(1.3 mg), and 18 (8 mg). Fraction 3J (9 mg) was subjected to preparative ODS HPLC [YMC 
Pack Pro C18, φ 10ID x 250 mm, flow rate: 2 mL/min, RI and UV detection at 254 nm] and 
eluted with 85% MeOH to afford compound 11 (1.5 mg) and 12 (1.2 mg). Fraction 3I (11 mg) 
was eluted with preparative ODS HPLC [YMC Pack Pro C18, (φ 10ID x 250 mm), flow rate: 2 
mL/min, RI and UV detection at 254 nm] using 85% MeOH to afford compound 11 (3.5 mg) 
and 18 (1.5 mg). Fraction 3H (78 mg) was subjected to preparative ODS HPLC [YMC Pack Pro 
C18, (φ 10ID x 250 mm), flow rate: 2 mL/min, RI and UV detection at 254 nm] and using 75% 
MeOH to afford fractions 7A to 7L and compound 9 (4 mg), 10 (8 mg), 18 (3.5 mg) and 19 (8 
mg). Fraction 1J (69 mg) was separated using preparative ODS HPLC [YMC Pack Pro C18, (φ 
10ID x 250 mm), flow rate: 2 mL/min, RI and UV detection at 254 nm] and eluted with 80% 
MeOH to afford compound 13 (3.5 mg), 14 (2 mg), 15 (4 mg), 20 (2 mg), and 21 (2 mg). 
Fraction 1O (59 mg) was eluted with preparative ODS HPLC [YMC Pack Pro C18, (φ 10ID x 
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250 mm), flow rate: 2 mL/min, RI and UV detection at 254 nm] using 70% MeOH to afford 
compound 16 (2 mg), 22 (1.2 mg) and 23 (0.9 mg). Fraction 7H (22 mg) was separated using 
preparative ODS HPLC [Inertsil ODS-3, (φ 10ID x 250 mm), flow rate: 2 mL/min, RI and UV 
detection at 254 nm] and eluted with 85% MeOH to afford compound 24 (2.5 mg), 25 (1.5 mg), 
and 26 (5.5 mg). 
 
1F
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1G
26
1H
30
1I
45
1J
69
1K
16
1L
67
1M
133
1N
247
1O
59
1P
254
1Q      
82 
 mg
hexane
10.0 g
EtOAc
3.0 g
BuOH
2.1 g
H2O
2.23 g
MeOH Extract of B. pandurata 
Rhizomes (18.5 g)
hexane/EtOAc Silica gel 60N
Solvent Fractionation
ODS CC
ODS HPLC
  
9
 
(16.0 mg)
10 (26.3 mg)
18 (8.0 mg) (New)
ODS HPLC
  
9
 
(4.0 mg)
10 (31.0 mg)
11 (5.0 mg)
12 (1.2 mg)
17 (3.8 mg) (New)
18 (5.0 mg) (New)
19 (8.0 mg) (New)
24 (2.5 mg) (New)
25 (1.5 mg) (New)
26 (5.5 mg) (New)
ODS CC
ODS HPLC
9 9
13 (3.5 mg)
14 (2.0 mg)
15 (4.0 mg) 
20 (2.0 mg) (New)
21 (2.0 mg)
16 (2.0 mg)
22 (1.2 mg) (New)
23 (0.9 mg)
ODS HPLC
 
Fig. 6-1: Isolation scheme of B. pandurata rhizomes 
 
Structure elucidation of 9-26 
Bioassay guided fractionation of B. pandurata rhizomes led to the isolation of seventeen 
pimarane diterpenes and one limonene type compounds - 6β-acetoxysandaracopimaradiene-
1α,9α-diol (9),3 sandaracopimaradiene-1α,6β,9α-triol (10),3 kaempulchraol C (11),4  
sandaracopimaradiene-1α,2α-diol (12),5 sandaracopimaradiene-6β,9α-diol-1-one (13),3 6β-
  
Red: Active Fraction 
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acetoxysandaracopimaradiene-9α-ol-1-one (14),3 sandaracopimaradiene-1α,9α-diol (15),3  
kaempulchraol H (16),4 pimaradiene-1α,6β-diol-14-one (17), pimaradiene-1α,7α,9α-triol (18), 
6β-acetoxypimaradiene-1α,7α,9α-triol (19), 6β-acetoxypimaradiene-7α,9α-diol (20), 1,11α-
dihydroxypimara-8(14)-15-diene (21),6 pimaradiene-7β,9α,11α-triol (22), 5α-hydroxy-2-oxo-p-
menth-6(1)-ene (23),7 14β-methoxypimaradiene-6β,7α-diol (24), 7α,14α-dimethoxypimaradiene-
6β-ol  (25), and 7α,14β-dimethoxypimaradiene-6β-ol  (26). Compounds 17-20, 22, and 24-26 are 
new compounds and remaining are known compounds.  
 
6β-acetoxysandaracopimaradiene-1α,9α-diol (9)3 
C22H34O4 (MW 362), ESIMS m/z [M+H]+ 363, [α]D26 - 39.3 (c 0.58, CHCl3), 1H and 13C NMR 
data, see Table 6-1. 
Sandaracopimaradiene-1α,6β,9α-triol (10)3 
C20H32O3 (MW 320), ESIMS m/z [M+Na]+ 343, [α]D26  + 27.4 (c 0.56, CHCl3), 1H and 13C NMR 
data, see Table 6-2. 
Kaempulchraol C (11)4   
 
C20H32O2 (MW 304), ESIMS m/z [M+H]+ 305, [α]D26 – 10.0 (c 0.1, MeOH), 1H and 13C NMR 
data, see Table 6-3. 
Sandaracopimaradiene-1α,2α-diol (12)5 
C20H32O2 (MW 304), ESIMS m/z [M+H]+ 305, [α]D26  + 36.9 (c 0.24, CHCl3), 1H and 13C NMR 
data, see Table 6-4. 
Sandaracopimaradiene-6β,9α-diol-1-one (13)3 
C20H30O3 (MW 318), ESIMS m/z [M+Na]+ 341, [α]D24  + 32.7 (c 0.73, CHCl3), 1H and 13C NMR 
data, see Table 6-5. 
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6β-acetoxysandaracopimaradiene-9α-ol-1-one (14)3 
C22H32O4 (MW 360), ESIMS m/z [M+Na]+ 383, [α]D24 - 34.7 (c 0.40, CHCl3), 1H and 13C NMR 
data, see Table 6-6. 
Sandaracopimaradiene-1α,9α-diol (15)3   
C20H32O2 (MW 304), ESIMS m/z [M+Na]+ 327, [α]D25  + 49.6 (c 0.64, CHCl3), 1H and 13C NMR 
data, see Table 6-7. 
Kaempulchraol H (16)4 
C20H32O3 (MW 320), ESIMS m/z [M+H]+ 321, [α]D25  - 7.0 (c 0.1, MeOH), 1H and 13C NMR 
data, see Table 6-8. 
Pimaradiene-1α,6β-diol-14-one (17) (New) 
C20H30O3 (MW 318), HRESIMS m/z [2M+Na]+ 659.4289 (Δ + 0.1 mmu) calculated as 
C40H60O6Na, 659.4288, IR (ATR): νmax 3470, 2924, 1651 cm-1, [α]D25 + 92.8 (c 0.3, CHCl3), 1H 
and 13C NMR and 2D NMR data, see Table 6-9. 
Pimaradiene-1α,7α,9α-triol (18) (New) 
C20H32O3 (MW 320), HRESIMS m/z [M+Na]+ 343.2255 (Δ + 0.6 mmu) calculated as 
C20H32O3Na, 343.2249, IR (ATR): νmax 3387, 3318, 2939 cm-1,   [α]D25  – 16.4 (c 0.3, CHCl3), 1H 
and 13C NMR and 2D NMR data, see Table 6-10. 
6β-acetoxypimaradiene-1α,7α,9α-triol (19) (New) 
C22H34O5 (MW 378), HRESIMS m/z [2M+Na]+ 779.4707 (Δ - 0.3 mmu) calculated as 
C44H68O10Na, 779.4710, IR (ATR): νmax 3362, 2923, 1733, 1242 cm-1,   [α]D25  – 33.5 (c 0.3, 
CHCl3), 1H and 13C NMR and 2D NMR data, see Table 6-11. 
6β-acetoxypimaradiene-7α,9α-diol (20) (New) 
C22H34O4 (MW 362), HRESIMS m/z [M+Na]+ 385.2318 (Δ – 3.7 mmu) calculated as 
C22H34O4Na, 385.2355, IR (ATR): νmax 3424, 2928, 1733, 1372, 1243 cm-1, [α]D25  + 23.4 (c 0.3, 
CHCl3), 1H and 13C NMR and 2D NMR data, see Table 6-12. 
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1,11α-dihydroxypimara-8(14)-15-diene (21)6 
C20H32O2 (MW 304), ESIMS m/z [M+Na]+ 327, [α]D25  + 29.0 (c 1.46, CHCl3), 1H and 13C NMR 
data, see Table 6-13. 
Pimaradiene-7β,9α,11α-triol (22) (New) 
C20H32O3 (MW 320), HRESIMS m/z [2M+Na]+ 663.4562 (Δ – 3.9 mmu) calculated as 
C40H64O6Na, 663.4601, IR (ATR): νmax 3853, 3418, 2944, 1456 cm-1, [α]D25 + 19.0 (c 0.3, 
CHCl3), 1H and 13C NMR and 2D NMR data, see Table 6-14. 
5α-hydroxy-2-oxo-p-menth-6(1)-ene (23)7 
C10H16O2 (MW 168), ESIMS m/z [M+Na]+ 191, [α]D24  + 36 (c 1.42, CHCl3), 1H and 13C NMR 
data, see Table 6-15. 
14β-methoxypimaradiene-6β,7α-diol (24) (New) 
C21H34O3 (MW 334), HRESIMS m/z [M+Na]+ 357.2359 (Δ – 4.6 mmu) calculated as 
C21H34O3Na, 357.2405, IR (ATR): νmax 3419, 2931, 1737, 1456 cm-1,  [α]D25 + 58.1 (c 0.3, 
CHCl3), 1H and 13C NMR and 2D NMR data, see Table 6-16. 
7α,14α-dimethoxypimaradiene-6β-ol (25) (New) 
C22H36O3 (MW 348), HRESIMS m/z [M+Na]+ 371.2565 (Δ + 0.3 mmu) calculated as 
C22H36O3Na, 371.2562, IR (ATR): νmax 3477, 2930, 1737, 1458 cm-1,   [α]D25 - 18.7 (c 0.3, 
CHCl3), 1H and 13C NMR and 2D NMR data, see Table 6-17. 
7α,14β-dimethoxypimaradiene-6β-ol (26) (New) 
C22H36O3 (MW 348), HRESIMS [M+Na]+ 371.2572 (Δ + 1.0 mmu) calculated as C22H36O3Na, 
371.2562, IR (ATR): νmax 3435, 2927, 1460, 1083 cm-1,   [α]D25  + 64.9 (c 0.5, CHCl3), 1H and 
13C NMR and 2D NMR data, see Table 6-18. 
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Table 6-1: NMR Spectroscopic data of compound 9 
 
 δH (J in Hz) (9) 
(600 MHz & CDCl3) 
δC (9) 
(150 MHz) 
1 3.99 (1H, d, 2.4) 75.3 
2 1.87 (1H, m) &  
1.47 (1H, m) 
26.6 
3 2.15 (2H, m) 37.2 
4  33.6 
5 2.38 (1H, d, 2.4) 42.0 
6 5.40 (1H, ddd, 3.9, 3, 2.4) 70.5 
7 2.73 (1H, ddd, 8.4, 3.9, 2.4) &  
1.87 (1H, m) 
35.5 
8  133.5 
9  77.0 
10  44.0 
11 1.78 (2H, m) 26.9 
12 1.47 (2H, m) 31.4 
13  37.7 
14 5.28 (1H, s) 133.4 
15 5.78 (1H, dd, 17.4, 10.8) 147.9 
16 4.91 (1H, dd, 10.8, 1.5) & 
4.96 (1H, dd, 17.4, 1.5) 
110.8 
17 1.04 (3H, s) 23.8 
18 1.03 (3H, s) 33.7 
19 1.01 (3H, s) 24.7 
20 1.10 (3H, s) 21.6 
21  170.5 
22 1.98 (3H, s) 21.9 
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Table 6-2: NMR Spectroscopic data of compound 10 
 
 δH (J in Hz) (10) 
(600 MHz & CDCl3) 
δC  (10) 
(150 MHz) 
1 3.95 (1H, d, 3.6) 75.6 
2 1.46 (2H, m ) 26.5 
3 1.86 (2H, m) 35.4 
4  33.8 
5 2.19 (1H, d, 2.4) 43.2 
6 4.37 (1H, s) 68.3 
7 2.86 (1H, ddd, 14.4, 3.6, 2.4)  
&  
2.02 (1H, dd, 14.4, 2.4) 
41.4 
8  133.8 
9  77.4 
10  43.7 
11 2.13 (1H, td, 13.2, 3.6) & 
1.78 (1H, dt, 13.2, 3.6) 
27.0 
12 1.66 (2H, td, 13.2, 3.6) 31.5 
13  37.8 
14 5.40 (1H, s) 134.2 
15 5.80 (1H, dd, 17.4, 10.8) 148.0 
16 4.93 (1H, d, 10.8) & 
4.98 (1H, d, 17.4) 
110.8 
17 1.05 (3H, s) 25.2 
18 1.07 (3H, s) 33.8 
19 1.27 (3H, s) 23.8 
20 1.12 (3H, s) 22.2 
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Table 6-3: NMR Spectroscopic data of compound 11 
 
 δH (J in Hz) (11) 
(600 MHz & CDCl3) 
 δC (11) 
(150 MHz) 
1 1.12 (1H, m) &  
1.71 (1H, m) 
39.9 
2 1.48 (1H, m) &  
1.67 (1H, m) 
19.3 
3 1.16 (1H, m) &  
1.44 (1H, m) 
43.1 
4  34.1 
5 1.16 (1H, m) 53.5 
6 4.52 (1H, d, 5.4) 65.7 
7 2.74 (1H, m) &  
2.00 (1H, m) 
40.2 
8  123.7 
9  140.6 
10  37.5 
11 2.17 (1H, m) &  
2.00 (1H, m) 
20.2 
12 1.71 (1H, m) &  
1.48 (1H, m) 
30.4 
13  40.1 
14 3.60 (1H, s) 77.5 
15 5.96 (1H, dd, 18, 10.8) 142.6 
16 5.15 (1H, d, 18) & 
5.19 (1H, d, 10.8) 
115.4 
17 1.03 (3H, s) 22.9 
18 1.21 (3H, s) 24.0 
19 0.96 (3H, s) 33.5 
20 1.36 (3H, s) 21.4 
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Table 6-4: NMR Spectroscopic data of compound 12 
 
 δH (J in Hz) (12) 
(600 MHz & CDCl3) 
δC  (12) 
(150 MHz) 
1 3.68 (1H, br s) 75.2 
2 3.90 (1H, m) 66.9 
3 1.66 (1H, m) &  
1.41 (1H, m) 
18.2 
4  42.7 
5 1.53 (1H, m) 46.8 
6 1.53 (1H, m) & 
1.30 (1H, td, 13.2, 4.2) 
22.1 
7 2.01 (1H, td, 13.2, 4.2) & 
2.23 (1H, m) 
35.5 
8  136.7 
9 2.33 (1H, t, 7.5) 43.4 
10  42.6 
11 1.66 (1H, m) &  
1.41 (1H, m) 
34.3 
12 1.41 (2H, m) 34.4 
13  37.4 
14 5.26 (1H, s) 129.5 
15 5.78 (1H, dd, 18, 10.2) 148.9 
16 4.91 (1H, d, 18) & 
4.86 (1H, d, 10.2) 
110.2 
17 1.03 (3H, s) 26.0 
18 0.89 (3H, s) 23.3 
19 0.94 (3H, s) 33.5 
20 0.80 (3H, s) 15.0 
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Table 6-5: NMR Spectroscopic data of compound 13 
 
 δH (J in Hz) (13) 
(600 MHz & CDCl3) 
 δC (13) 
(150 MHz) 
1  218.4 
2 2.10 (2H, m) 37.5 
3 2.10 (2H, m) 42.7 
4  34.0 
5 2.24 (1H, d, 1.8) 50.3 
6 4.28 (1H, m) 68.8 
7 2.83 (2H, m) 42.1 
8  131.9 
9  75.0 
10  56.2 
11 1.70 (2H, m) 28.4 
12 1.70 (2H, m) 31.9 
13  37.8 
14 5.47 (1H, s) 136.9 
15 5.76 (1H, dd, 10.8, 17.4) 147.4 
16 4.92 (1H, d, 10.8) & 
4.96 (1H, d, 17.4) 
111.2 
17 1.05 (3H, s) 24.7 
18 1.06 (3H, s) 32.5 
19 1.42 (3H, s) 20.4 
20 1.44 (3H, s) 24.5 
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Table 6-6: NMR Spectroscopic data of compound 14 
 
 δH (J in Hz) (14) 
(600 MHz & CDCl3) 
 δC (14) 
(150 MHz) 
1  217.8 
2 2.75 (1H, td, 12, 4.8) & 
1.68 (1H, m) 
37.8 
3 1.68 (2H, m) 37.7 
4  31.8 
5 2.47 (1H, d,1.2) 48.6 
6 5.31 (1H, quartet, 3) 70.9 
7 2.65 (1H, dt, 14, 3) & 
1.68 (1H, m) 
41.8 
8  131.7 
9  75.0 
10  56.4 
11 2.20 (2H, m) 28.4 
12 2.20 (2H, m) 37.6 
13  33.7 
14 5.36 (1H, s) 136.2 
15 5.78 (1H, dd, 10.8, 17.4) 147.3 
16 4.93 (1H, d, 10.8) & 
4.96 (1H, d, 17.4) 
111.2 
17 1.03 (3H, s) 24.6 
18 1.43 (3H, s) 32.2 
19 1.16 (3H, s) 20.1 
20 1.06 (3H, s) 24.3 
21  170.3 
22 2.01 (3H, s) 21.7 
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Table 6-7: NMR Spectroscopic data of compound 15 
 
 δH (J in Hz) (15) 
(600 MHz & CDCl3) 
 δC (15) 
(150 MHz) 
1 4.00 (1H, br s) 74.0 
2 1.81 (2H, m) 26.3 
3 1.81 (1H, m) & 
1.12 (1H, dd, 3, 12.6) 
33.8 
4  32.8 
5 2.22 (1H, dd, 3, 12.6) 39.7 
6 1.66 (1H, m) & 
1.37 (1H, dd, 3, 12.6) 
22.1 
7 2.04 (1H, m) &  
2.43 (1H, m) 
31.1 
8  136.8 
9  77.4 
10  43.4 
11 2.04 (1H, m) & 
1.57 (1H, m) 
26.8 
12 1.50 (2H, m) 31.4 
13  37.6 
14 5.26 (1H, br s) 131.4 
15 5.80 (1H, dd, 10.8, 18) 148.4 
16 4.91 (1H, d, 10.8) & 
4.96 (1H, d, 18) 
110.5 
17 1.01 (3H, s) 23.6 
18 0.88 (3H, s) 33.6 
19 0.83 (3H, s) 18.6 
20 0.95 (3H, s) 22.7 
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Table 6-8: NMR Spectroscopic data of compound 16 
 
 δH (J in Hz) (16) 
(600 MHz & CDCl3) 
 δC (16) 
(150 MHz) 
1 3.62 (1H, br s) 75.1 
2 2.01 (1H, m) &  
2.09 (1H, m) 
29.6 
3 3.51 (1H, br s) 79.3 
4  38.6 
5 1.76 (1H, br s) 44.2 
6 4.31 (1H, br s) 69.0 
7 2.40 (1H, d, 14.4) & 
2.25 (1H, d, 14.4) 
45.7 
8  133.7 
9 2.52 (1H, t, 7.2) 42.4 
10  43.3 
11 1.63 (1H, m) &  
1.56 (1H, m) 
17.7 
12 1.42 (1H, m) &  
1.47 (1H, m) 
34.1 
13  37.7 
14 5.42 (1H, br s) 133.0 
15 5.76 (1H, dd, 10.2, 14.4) 148.1 
16 4.91 (2H, d, 14.4) 110.8 
17 1.07 (3H, s) 26.7 
18 1.25 (3H, s) 24.0 
19 1.10 (3H, s) 28.6 
20 1.06 (3H, s) 18.4 
 
Structure elucidation of new compounds 
Compound 17 was isolated as a colorless amorphous solid and molecular formula was 
determined by HRESIMS as C20H30O3 (MW 318). The IR spectrum of 17 showed absorption 
band due to hydroxyl and olefinic groups at 3470 and 1651 cm-1 respectively. 13C NMR 
spectrum (Table 6-9) revealed 20 signals including four sp3 methyls (δC 24.2, 23.9, 34.7, and 
21.5), five sp3 methylenes (δC  26.8, 36.7, 36.1, 22.3, and 36.6), three sp3 methines including 
two oxygenated (δC  73.8, 46.6, and 65.1), one sp2 methylene (δC  114.8), one sp2 methine (δC  
41.9), one carbonyl (δC  204.6), three sp3 quaternary carbons (δC  33.8, 45.0, and 48.6),  and two 
sp2 quaternary carbons (δC 128.7 and 166.4). The 1H NMR spectrum (Table 6-9) displayed 
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signals due to terminal vinyl group [δH 5.90 (dd, J = 10.8, 17.4 Hz, H-15), 5.04 (d, J = 10.8 Hz, 
H-16a), 4.94 (d, J = 17.4 Hz, H-16b)], two oxygenated methines [δH 3.81 (t, J = 1.8, Hz, H-1) 
and 4.55 (br d, J = 4.8,  Hz, H-6)], and four tertiary methyls [δH 1.15 (s, H3-17), 1.23 (s, H3-18), 
1.01 (s, H3-19), and 1.43 (s, H3-20)]. The aforementioned spectroscopic data were consistent 
with a pimarane diterpene type compound,8 which was confirmed by HMBC correlations. 
Specifically, HMBC correlations from H3-17 to C-12, C-13, C-14, and C-15, from H-16 to C-13, 
and from H-12 to C-13 and C-15 indicated that a methyl and a vinyl were connected to C-13 and 
a carbonyl was present at C-14. HMBC correlations from H3-20 to C-1 and C-9, from H-6 to C-
5 and C-8, and from H-1 to C-3 and C-5 suggested that hydroxyl groups were present at C-1 and 
C-6, and a double bond was located between C-8 and C-9. 
 
The relative stereochemistry of 17 was determined by comparing 13C NMR chemical shift with 
known compound kaempulchraol G,4 analysis of coupling constant, and NOE correlations. C-6 
and C-13 have almost similar 13C NMR chemical shift of 17 (δC 65.1 and 48.6) and 
kaempulchraol G4 (δC  64.9 and 47.7), so methyl at C-13 was β-axially oriented (Fig. 6-3). The 
small coupling constant for H-1 [δH 3.81 (t, J = 1.8 Hz)] and H-2 [δH 2.04 (ddt, J = 1.8 Hz)] 
indicated H-1 was in equatorial position and coupled with H-2 axial proton with 1.8 Hz and so 
the hydroxyl substituent at C-1 to be α-axially oriented. H-1 and H-20 also showed good NOE 
correlations and so methyl at C-10 was β-axially oriented (Fig. 6-3). H-5 and H-6 displayed 
NOE correlations and so H-5 was α-axially oriented. A signal at δH  4.55 (br d, J = 4.8 Hz, H-6) 
was attributable to equatorial proton geminal to hydroxyl group and coupled with vicinal axial 
proton [δH  2.27 (dt, J = 4.8 Hz, H-7)] and so hydroxyl at C-6 was β-axially oriented which was 
supported by NOE correlations with H-5 and also comparison of known compound 13C NMR 
coupling constant. So, the compound 17 was pimaradiene-1α,6β-diol-14-one. 
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                               Fig. 6-2: 1H and 13C NMR of 17 
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Fig. 6-3: (a) COSY (Bold line) and Key HMBC (arrows) of 17; (b) structure of kaempulchraol 
G; (c) Chair conformation with NOE correlations of 17. 
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Table 6-9: NMR Spectroscopic data of compound 17 
 
 δH (J in Hz) (17) 
(600 MHz & CD3OD) 
 δC (17) 
 (150 MHz) 
COSY HMBC 
1 3.81 (1H, t, 1.8) 73.4 1.53 46.6, 36.7 
2 2.04 (1H, ddt, 1.8, 4.2, 13.8)  
& 1.53 (1H, dq, 3, 13.8) 
26.8 1.53, 1.68 & 
3.81, 2.04, 1.68 
 
33.8, 36.7 
3 1.68 (1H, td, 13.8, 4.2) & 
1.11 (1H, dt, 13.8, 3) 
36.7 1.53, 2.04 23.9, 26.8, 34.7 
4  33.8   
5 1.62 (1H, s) 46.6 4.55 21.5, 23.9, 34.7, 45.0, 65.1, 73.4, 
166.4 
6 4.55 (1H, br d, 4.8) 65.1 1.62, 2.27, 2.50 45.0, 128.7 
7 2.50 (1H, dd, 1.2, 18) & 
2.27 (1H, dt, 18, 4.8) 
36.1 4.55, 2.27 & 
4.55, 2.50 
46.6, 65.1, 128.7, 166.4 
& 128.7, 166.4 
8  128.7   
9  166.4   
10  45.0   
11 2.66 (1H, m) &  
2.45 (1H, m) 
22.3 1.83, 2.45 & 
2.66, 1.97, 1.83 
 
45.0, 128.7 
12 1.97 (1H, dt, 13.2, 4.2) & 
1.83 (1H, td, 13.2, 4.2) 
36.6 1.83, 2.45 & 
2.66, 1.97, 2.45   
22.3, 48.6, 141.9, 166.4, 204.6 & 
22.3, 48.6, 141.9, 166.4, 204.6 
13  48.6   
14  204.6   
15 5.90 (1H, dd, 10.8, 17.4) 141.9 5.04, 4.94 24.2, 36.6, 48.6, 204.6 
16 5.04 (1H, d, 10.8) &  
4.94 (1H, d, 17.4) 
114.8 5.90 & 
5.90 
48.6 & 
48.6, 141.9 
17 1.15 (3H, s) 24.2  36.6, 48.6, 141.9, 204.6 
18 1.23 (3H, s) 23.9  33.8, 36.7, 46.6 
19 1.01 (3H, s) 34.7  23.9, 33.8, 46.6 
20 1.43 (3H, s) 21.5  45.0, 73.4, 166.4 
 
 
Compound 18 was obtained as a colorless amorphous solid and molecular formula was assigned 
by HRESIMS as C20H32O3 (MW 320). The IR spectrum revealed absorption bands at 3387 and 
2939 cm-1 ascribable to be the presence of hydroxy and olefinic groups. The 1H NMR spectrum 
(Table 6-10) of 18 showed signals for a pimarane diterpene type skeleton including terminal 
vinylic protons [δH 5.82 (dd, J = 10.5, 17.7 Hz, H-15), 5.00 (d, J = 17.7 Hz, H-16a), 4.96 (d, J = 
10.5 Hz, H-16b)], an olefinic methine [δH 5.58 (d, J = 1.2 Hz, H-14)], and four methyl singlets 
[δH  1.01 (H3-17), 0.90 (H3-18). 0.98 (H3-19), and 0.79 (H3-20)]. Analysis of HMQC and 13C 
NMR (Table 6-10) spectroscopic data of 18 suggested the presence of four olefinic carbons (δC 
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136.0, 137.0, 147.5, and 111.2), three sp3 methines including two oxygenated (δC 73.7, 34.0, and 
74.0), five quaternary carbons (δC 32.6, 136.0, 78.6, 43.1, and 37.7), five methylenes (δC 26.2, 
33.6, 30.1, 26.0, and 30.6), and four methyls (δC 23.0, 22.5, 33.6, and 18.1). The HMBC 
correlations between H-1 and C-3/C-20 and between H-7 and C-5/C-9 showed the attachment of 
two hydroxyl groups at C-1 and C-7. HMBC correlations from H3-17 to C-12, C-13, C-14, and 
C-15, from H-16 to C-13, and from H-12 to C-13, C-14, and C-15 revealed that a methyl and a 
vinyl were connected to C-13. These data suggested that 18 was a pimarane diterpene.  
 
The relative stereochemistry of 18 was assigned by comparing 13C NMR chemical shift with 
known compound sandaracopimaradien-1α,9α-diol3 and analysis of coupling constant. C-9, C-
10, and C-13 have almost similar 13C NMR chemical shift of 18 (δC  78.6, 43.1 and 37.7) and 
sandaracopimaradien-1α,9α-diol3 (δC  77.4, 43.4 and 37.6), so methyls at C-10 and C-13 are β-
axially oriented and hydroxyl at C-9 is α-axially oriented. H-1 [3.99 (s)] showed very small 
coupling constant which indicate equatorial-axial coupling with H-2 and so hydroxyl at C-1 was 
α-axially oriented which was supported by comparing with known compound (Fig. 6-5). Proton 
H-5 was in axial position depending upon its coupling constant (dd, J = 3.0, 13.2 Hz). Between 
H-5 and H-6, axial-axial coupling constant was (J = 13.8 Hz) and axial-equatorial coupling 
constant was (J = 3.0 Hz). Similarly, between H-6 and H-7, axial-equatorial coupling constant 
was (J = 3.0 Hz). So, H-7 was assigned as equatorial and hydroxyl at C-7 was α-axially oriented 
(Fig. 6-5). So, the compound 18 was pimaradiene-1α,7α,9α-triol. 
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                               Fig. 6-4: 1H and 13C NMR of 18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig. 6-5: (a) COSY (Bold line) and Key HMBC (arrows) of 18; (b) structure of 
sandaracopimaradien-1α,9α-diol; (c) Chair conformation with NOE correlations of 18. 
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Table 6-10: NMR Spectroscopic data of compound 18 
 
 δH (J in Hz) (18) 
(600 MHz & CDCl3) 
 δC (18) 
(150 MHz) 
COSY HMBC 
1 3.99 (1H, s) 73.7 1.52, 1.76 33.6, 18.1 
2 1.52 (1H, qd, 3, 13.8) & 
1.76 (1H, m) 
26.2 3.99, 1.15, 1.76 & 
3.99, 1.15, 1.52 
32.6, 43.1, 73.7 & 
33.6,  
3 1.15 (1H, dt, 13.8, 3) & 
1.85 (1H, td, 13.8, 3) 
33.6 1.52, 1.76, 1.85 & 
1.15 
22.5, 26.2, 33.6, 73.7 & 
22.5, 26.2, 33.6, 73.7 
4  32.6   
5 2.43 (1H, dd, 3, 13.8) 34.0 1.62, 1.85 18.1, 22.5, 30.1, 33.6, 43.1, 73.7, 
78.6 
6 1.62 (1H, td, 13.8, 3) & 
 1.85 (1H, dt, 13.8, 3) 
30.1 4.20, 2.43, 1.85 & 
4.20, 2.43, 1.62 
34.0, 43.1 & 
43.1, 136.0 
7 4.20 (1H, t, 3) 74.0 1.62, 1.85 78.6, 34.0 
8  136.0   
9  78.6   
10  43.1   
11 1.76 (1H, m) & 
1.95 (1H, td, 13.8, 3) 
26.0 1.95 & 
1.43, 1.76 
30.6, 37.7, 78.6, 136.0 & 30.6, 
37.7, 43.1 
12 1.43 (1H, m) & 
1.81 (1H, dd, 3, 13.8) 
30.6 1.95, 1.81 &  
1.43 
23.0, 26.0, 37.7, 78.6, 137.0 
13  37.7   
14 5.58 (1H, d, 1.2) 137.0  23.0, 30.6, 37.7, 74.0, 78.6, 147.5 
15 5.82 (1H, dd, 10.5, 17.7) 147.5 5.00, 4.96 23.0, 30.6, 37.7, 137.0 
16 5.00 (1H, d, 17.7) & 
4.96 (1H, d, 10.5) 
111.2 5.82 & 
5.82 
37.7, 147.5 
17 1.01 (3H, s) 23.0  30.6, 37.7, 137.0, 147.5 
18 0.90 (3H, s) 22.5  32.6, 33.6 
19 0.98 (3H, s) 33.6  22.5, 32.6 
20 0.79 (3H, s) 18.1  34.0, 43.1, 73.7, 78.6 
 
Compound 19 was isolated as colorless amorphous solid and its molecular formula C22H34O5 
(MW378) was established by HRESIMS. Compound 19 was also a pimarane diterpene and has 
structural similarity with 18. 1H and 13C NMR spectrum (Table 6-11) signals revealed the 
presence of one additional acetoxy group at C-6. The 1H NMR spectrum showed signals for four 
tertiary methyl groups [δH 1.05 (H3-17), 1.02 (H3-18). 1.07 (H3-19), and 1.07 (H3-20)] and three 
signals of an ABX system corresponding to the three vinyl protons at C-13 [δH 5.82 (dd, J = 10.8, 
17.4 Hz, H-15), 5.03 (d, J = 17.4 Hz, H-16a), 4.97 (d, J = 10.8 Hz, H-16b)] confirming a 
pimarane diterpene derivative.8 HMBC correlations from H-1 to C-3, C-5, and C-20 and from H-
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7 to C-5, C-9, and C-14 indicated the position of hydroxyl at C-1 and C-7. HMBC correlations 
between H-6 and C-8/C-10/ C-21 suggested the position of acetoxy group at C-6. 
 
The relative stereochemistry of 19 was established by comparing 13C NMR chemical shift with 
known compound 6β-acetoxysandaracopimaradien-1α,9α-diol,3 analysis of coupling constant, 
and NOE correlations. C-1, C-9, C-10, and C-13 have almost similar 13C NMR chemical shift of 
19 (δC 75.4, 79.0, 43.8, and 37.9) and 6β-acetoxysandaracopimaradien-1α,9α-diol3 (δC 75.2, 77.2, 
44.0, and 37.8), so hydroxyls at C-1 and C-9 were α-axially oriented and methyls at C-10 and C-
13 were β-axially oriented. Small coupling constant at H-1 [d, (J = 1.2 Hz)] also depicted the α-
axial orientation of hydroxyl group at C-1. Between H-5 and H-6, axial-equatorial coupling 
constant was (J = 2.4) and between H-6 and H-7, equatorial-equatorial coupling constant was (J 
= 2.4) and so acetoxy at C-6 to be β-axial and hydroxyl group at C-7 was α- axially oriented 
which were also in agreement with NOE correlations (Fig. 6-7). So, the compound 19 was 6β-
acetoxypimaradiene-1α,7α,9α-triol.   
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Fig. 6-6: 1H and 13C NMR of 19 
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Fig. 6-7: (a) COSY (Bold line) and Key HMBC (arrows) of 19; (b) structure of 6β-
acetoxysandaracopimaradien-1α,9α-diol; (c) Chair conformation with NOE correlations of 19. 
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Table 6-11: NMR Spectroscopic data of compound 19 
 
 δH (J in Hz) (19) 
(600 MHz & CDCl3) 
 δC (19) 
(150 MHz) 
COSY HMBC 
1 4.02 (1H, d, 1.2) 75.4 1.50 21.2, 26.5, 35.5, 37.2, 43.8 
2 1.50 (1H, m) & 
1.88 (1H, m) 
26.5 4.02, 1.88, 1.14 
& 1.50 
33.4, 43.8, 75.4 & 
35.5 
3 1.14 (1H, dt, 12.6, 2.4)  
& 1.93 (1H, td, 12.6, 3) 
35.5 1.93, 1.50 & 
1.14 
24.8, 26.5, 33.4, 37.2, 75.4 &  
26.5, 33.6 
4  33.4   
5 2.59 (1H, d, 2.4) 37.2 5.38 21.2, 24.8, 33.4, 43.8, 73.8, 79.0 
6 5.38 (1H, t, 2.4) 73.8 2.59, 3.85 33.4, 37.2, 43.8, 133.0, 170.2 
7 3.85 (1H, d, 2.4) 75.2 5.38 37.2, 73.8, 79.0, 133.0, 139.8 
8  133.0   
9  79.0   
10  43.8   
11 1.76 (1H, dt, 13.8, 3) & 
2.06 (1H, td, 13.8, 3) 
26.5 2.06, 1.44 & 
1.82, 1.76, 1.44 
31.0, 37.9, 79.0, 133.0 &  
21.2, 31.0, 37.9, 43.8 
12 1.44 (1H, m) & 
1.82 (1H, dd, 3, 13.8) 
31.0 2.06, 1.82, 1.76 
& 2.06, 1.44 
23.2, 26.5, 37.9, 79.0, 139.8 & 
23.2, 26.5, 37.9, 79.0, 139.8, 147.2  
13  37.9   
14 5.66 (1H, s) 139.8  23.2, 31.0, 37.9, 75.2, 79.0, 147.2 
15 5.82 (1H, dd, 10.8, 
17.4) 
147.2 5.03, 4.94 23.2, 31.0, 37.9, 139.8,  
16 4.97 (1H, d, 10.8) & 
5.03 (1H, d, 17.4) 
111.5 5.82 & 
5.82 
37.9 & 
37.9, 147.2 
17 1.05 (3H, s) 23.2  31.0, 37.9, 139.8, 147.2 
18 1.02 (3H, s) 24.8  33.6, 33.5, 37.2 
19 1.07 (3H, s)  33.6  24.8, 33.4, 35.5, 37.2 
20 1.07 (3H, s) 21.2  37.2, 43.8, 75.4, 79.0 
21  170.2   
22 1.99 (3H, s) 21.7  73.8, 170.2 
 
Compound 20 was separated as a colorless amorphous solid and molecular formula of was 
established by HRESIMS as C22H34O4 (MW 362). Compound 20 has structural similarity with 
19 and lack of hydroxyl C-1. 1H and 13C NMR  (Table 6-12) spectrum signals showed four 
quaternary methyls and one vinyl group which is a characteristic of pimarane diterpene.8 The 
HMBC correlations between H-6 [δH 5.29 (t, J = 2.4 Hz)] and C-8/C-10/C-21 and between H-7 
[δH 3.89 (d, J = 2.4 Hz)] and C-5/C-9/C-14 confirmed the position of acetoxy and hydroxyl 
group at C-6 and C-7 respectively. 
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The relative stereochemistry of 20 was assigned by comparing 13C NMR chemical shift with 
known compound 6β-acetoxysandaracopimaradien-1α,9α-diol,3 analysis of coupling constant, 
and NOE correlations. C-5, C-9, C-10, and C-13 have almost similar 13C NMR chemical shift of 
20 (δC  41.7, 76.0, 42.8, and 38.1) and 6β-acetoxysandaracopimaradien-1α,9α-diol3 (δC  42.1, 
77.2, 44.0, and 37.8), so H-5 was axial, hydroxyls at C-9 was α-axially oriented, and methyls at 
C-10 and C-13 were β-axially oriented. Axial proton H-5 [2.14 (d, J = 2.4)] showed coupling 
with equatorial H-6 [5.29 (t, J = 2.4)] and between H-6 and H-7, equatorial-equatorial coupling 
constant was (J = 2.4) and so acetoxy at C-6 to be β-axial and hydroxyl at C-7 was α- axially 
oriented which were also supported by NOE correlations (Fig. 6-9). So, the compound 20 was 
6β-acetoxypimaradiene-7α,9α-diol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                       
Fig. 6-8: 1H and 13C NMR of 20 
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Fig. 6-9: (a) COSY (Bold line) and Key HMBC (arrows) of 20; (b) structure of 6β-
acetoxysandaracopimaradien-1α,9α-diol; (c) Chair conformation with NOE correlations of 20. 
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Table 6-12: NMR Spectroscopic data of compound 20 
 
 δH (J in Hz) (20) 
(600 MHz & CDCl3) 
δC (20) 
(150 MHz) 
COSY HMBC 
1 1.77 (1H, td, 13.2, 3.6) & 
1.37 (1H, m) 
33.7 1.37 & 
1.27, 1.77 
20.8, 42.8, 76.0 & 
42.8 
2 1.27 (1H, dd, 3.6, 13.2) & 
1.37 (1H, m) 
43.7 1.37, 1.57 &  
1.27, 1.77 
33.7, 33.8 & 
42.8 
3 1.57 (1H, dt, 13.2, 3.6) & 
1.50 (1H, m) 
18.6 1.27, 1.50 & 
1.57 
33.7, 33.8 
 
4  33.8   
5 2.14 (H, d, 2.4) 41.7 5.29 20.8, 24.0, 33.8, 42.8, 76.0 
6 5.29 (H, t, 2.4) 73.4 3.89, 2.14 33.8, 42.8, 75.6, 134.0, 170.4 
7 3.89 (H, d, 2.4) 75.6 5.29 41.7, 73.4, 76.0, 134.0, 140.1 
8  134.0   
9  76.0   
10  42.8   
11 1.27 (1H, dd, 3.6, 13.2) & 
1.50 (1H, m) 
26.4 1.50 & 
1.27, 1.71 
38.1 & 
31.4, 38.1, 42.8, 76.0, 134.0 
12 1.71 (2H, td, 13.2, 3.6) 31.4 1.50 26.4, 38.1, 76.0, 147.2 
13  38.1   
14 5.66 (H, s) 140.1  23.5, 31.4, 38.1, 75.6, 76.0, 147.2 
15 5.81 (H, dd, 10.8, 17.7) 147.2 5.00, 4.97 23.5, 31.4, 38.1, 140.1  
16 5.00 (H, d, 17.7) & 
4.97 (H, d, 10.8) 
111.4 5.81 & 
5.81 
38.1, 147.2 & 
38.1 
17 1.05 (3H, s) 23.5  31.4, 38.1, 140.1, 147.2 
18 1.01 (3H, s) 24.0  33.8, 41.7 
19 1.00 (3H, s) 33.6  24.0, 33.8, 41.7 
20 1.15 (3H, s) 20.8  33.7, 42.8, 76.0 
21  170.4   
22 2.00 (3H, s) 21.6  73.4, 170.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
73 
 
Table 6-13: NMR Spectroscopic data of compound 21 
 
 δH (J in Hz) (21) 
(600 MHz & CDCl3) 
δC (21) 
(150 MHz) 
1 3.77 (1H, br s) 72.6 
2 1.88 (1H, m) & 
1.63 (1H, m) 
25.3 
3 1.76 (1H, dd, 3, 13.8) & 
1.15 (1H, dt, 13.8, 3) 
34.2 
4  33.4 
5 1.54 (1H, dd, 2.4, 13.2) 47.5 
6 1.63 (1H, m) & 
1.32 (1H, dd, 4.8, 13.2) 
22.6 
7 2.25 (2H, d, 7.2) & 
2.01 (3H, td, 13.2, 4.8) 
35.4 
8  136.6 
9 2.25 (1H, d, 7.2) 52.7 
10  42.7 
11 4.10 (1H, ddd, 4.8, 7.2, 12) 65.9 
12 1.70 (1H, dd, 4.8, 12) & 
1.48 (1H, t, 12) 
44.4 
13  38.3 
14 5.28 (1H, s) 128.3 
15 5.78 (1H, dd, 10.8, 17.7) 148.3 
16 4.96 (1H, d, 17.7) & 
4.91 (1H, d, 10.8) 
110.3 
17 1.03 (3H, s) 25.3 
18 0.85 (3H, s) 22.3 
19 0.91 (3H, s) 33.2 
20 0.80 (3H, s) 15.6 
 
 
 
Compound 22 was isolated as a colorless amorphous solid, and HRESIMS and 13C NMR data 
(Table 6-14) suggested its molecular formula C20H32O3 (MW 320). Compound 22 and 18 have 
same molecular formula but have different position and configuration of hydroxyl groups. Thus, 
22 was proposed to be a trihydroxy derivative of pimarane diterpene. On the basis of HMBC 
correlations of H-7 [δH 4.42 (ddd, J = 2.4, 6, 12 Hz)] to C-8/C-14 and H-11 [δH 4.13 (dd, J = 4.8, 
10.2 Hz)] to C-10/C-12/C-13, the location of two hydroxy groups were at C-7 and C-11. 
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The relative stereochemistry of 22 was assigned by comparing 13C NMR chemical shift with 
known compound acerifolin B,9 analysis of coupling constant, and NOE correlations. C-9, C-10, 
C-11, and C-13 have almost similar 13C NMR chemical shift of 22 (δC 75.8, 42.9, 66.2, and 37.8) 
and acerifolin B9 (δC 75.5, 42.3, 66.8, and 38.1), so hydroxyls at C-9 was α-axial and C-11 was 
α-equatorially oriented, and methyls at C-10 and C-13 were β-axially oriented. Large coupling 
constant of H-11 [δH 4.13 (dd, J = 4.8, 10.2 Hz)] also supported the α-equatorial orientation of 
hydroxyl at C-11. Proton H-5 was α-axially oriented depending upon its coupling constant [δH 
1.90 (dd, J = 2.4, 12 Hz)]. Between H-5 and H-6, axial-axial coupling constant was (J = 12) and 
between H-6 and H-7, axial-axial coupling constant was (J = 12). So, hydroxyl at C-7 was β-
equatorially oriented. In addition, H-5 and H-7 showed good NOE-correlations that also 
established β-equatorial orientation of hydroxyl at C-7 (Fig. 6-11). Hence, the structure of 22 
was concluded to be pimaradiene-7β,9α,11α-triol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                       Fig. 6-10: 1H and 13C NMR of 22 
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Fig. 6-11: (a) COSY (Bold line) and Key HMBC (arrows) of 22; (b) structure of acerifolin B; 
(c) Chair conformation with NOE correlations of 22. 
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Table 6-14: NMR Spectroscopic data of compound 22 
 
 δH (J in Hz) (22) 
(600 MHz & CDCl3) 
 δC (22) 
(150 MHz) 
COSY HMBC 
1 1.49 (2H, m) 33.9 1.49 41.2, 42.4 
2 1.49 (2H, m) 18.7 1.38, 1.49 41.2, 42.9 
3  1.49 (1H, m) & 
1.38 (1H, m) 
41.2 1.49, 1.38 & 
1.49 
42.4 
4  33.1   
5 1.90 (1H, dd, 2.4, 12) 42.4 1.26 42.9, 32.6, 22.2, 17.9 
6 1.26 (1H, q, 12) & 
1.99 (1H, ddd, 2.4, 6, 12) 
32.6 4.42, 1.99, 1.90 & 
1.26 
42.4, 69.8 & 
42.9, 69.8, 139.9 
7 4.42 (1H, ddd, 2.4, 6, 12) 69.8 1.26 139.9, 127.3 
8  139.9   
9  75.8   
10  42.9   
11 4.13 (1H, dd, 4.8, 10.2) 66.2 1.63 37.8, 40.7, 42.9 
12 1.63 (2H, m) 40.7 4.13 25.1, 37.8, 66.2, 75.8, 127.3, 
147.8 
13  37.8   
14 5.73 (1H, br s) 127.3  37.8, 40.7, 69.8, 75.8, 147.8 
15 5.86 (1H, dd, 10.8, 17.4) 147.8 5.02, 4.96 25.1, 37.8, 40.7, 127.3 
16 5.02 (1H, d, 17.4) & 
4.96 (1H, d, 10.8) 
111.3 5.86 & 
5.86 
37.8, 147.8 & 
37.8, 147.8 
17 1.08 (3H, s) 25.1  37.8, 40.7, 127.3, 147.8 
18 0.86 (3H, s) 22.2  33.1, 33.9, 41.2 
19 0.93 (3H, s) 33.9  22.2, 33.1, 42.4 
20 0.91 (3H, s) 17.9  33.9, 42.9, 75.8 
 
 
Table 6-15: NMR Spectroscopic data of compound 23 
 
 δH (J in Hz) (23) 
(600 MHz & CDCl3) 
δC (23) 
(150 MHz) 
1  135.2 
2  199.9 
3 2.09 (1H, dd, 13.8, 16.2) & 
2.45 (1H, dd, 3.6, 16.2) 
36.3 
4 1.93 (1H, m) 50.1 
5 4.33 (1H, dt, 9.6, 1.8) 69.1 
6 6.63 (1H, t, 1.8) 148.3 
7 1.76 (3H, t, 1.8) 15.3 
8 2.16 (1H, m) 26.3 
9 0.87 (3H, d, 7.2) 16.6 
10 0.95 (3H, d, 7.2) 20.5 
 
 
O
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Compound 24 was obtained as colorless amorphous solid and its molecular formula was 
assigned as C21H34O3 (MW 334) on the basis of HRESIMS. The 1H NMR spectrum (Table 6-16) 
displayed singlets for four tertiary methyl groups [δH 1.10 (H3-17), 1.21 (H3-18). 0.99 (H3-19), 
and 1.32 (H3-20)] and a mono-substituted vinyl group [δH 5.72 (dd, J = 11.1, 17.4 Hz, H-15), 
5.05 (d, J = 17.4 Hz, H-16a), 4.97 (d, J = 11.1 Hz, H-16b)], which supported the structure of 
pimarane diterpene.8 The 13C NMR (Table 6-16) spectrum showed four olefinic carbons (δC 
125.6, 1 46.9, 143.9, 112.7), four methines including three oxygenated ones (δC  49.1, 71.8, 71.6, 
81.8), five methylenes (δC 39.1, 19.0, 42.8, 21.3, 29.7), three quaternary carbons (δC 33.7, 38.1, 
40.0),  and five methyls including oxygenated one (δC 23.5, 24.1, 33.4, 21.8, 62.0).  The HMBC 
correlations from H-6 [δH 4.27, s] to C-5, C-8, and C-10 and from H-7 [δH 3.96, s] to C-5, C-8, 
C-9, and C-14 and from H-14 [δH 3.48, s] to C-9, C-15, C-17, and C-21 assigned the position of 
hydroxyls at C-6 and C-7, and the methoxy group at C-14. 
 
The relative configuration of 24 was determined by comparing 13C NMR chemical shift with 
known compound curcumrinol B,10 analysis of coupling constant, and NOE correlations. C-5, C-
6, C-7, C-10, and C-13 have almost similar 13C NMR chemical shift of 24 (δC 49.1, 71.8, 71.6, 
38.1, and 40.0) and curcumrinol B10 (δC  48.7, 70.6, 70.6, 37.9, and 38.8), so H-5 was in axial, 
hydroxyls at C-6 was β-axial and C-7 was α- axially oriented, and methyls at C-10 and C-13 
were β-axially oriented. Small coupling constant of H-6 [δH 4.27, s], H-7 [δH 3.96, s], and H-14 
[δH 3.48, s] suggested the hydroxyl at C-6 to be β-axial, hydroxyl at C-7 was α-axial, and 
methoxy at C-14 was β-equatorially oriented (Fig. 6-13). In addition, equatorial H-7 showed 
NOE correlations with equatorial methoxy proton at C-14 and axial H-14 showed NOE 
correlation with equatorial H-15 and so, methoxy at C-14 was β-equatorially oriented (Fig. 6-13). 
The structure of compound 24 was elucidated as 14β-metoxypimaradiene-6β,7α-diol. 
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                            Fig. 6-12: 1H and 13C NMR of 24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Fig. 6-13: (a) COSY (Bold line) and Key HMBC (arrows) of 24; (b) structure of curcumrinol B; 
(c) Chair conformation with NOE correlations of 24. 
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Table 6-16: NMR Spectroscopic data of compound 24 
 
 δH (J in Hz) (24) 
(600 MHz & CDCl3) 
 δC (24) 
(150 MHz) 
COSY HMBC 
1 1.68 (1H, m) & 
1.61 (1H, m) 
39.1 1.48 & 
1.48 
42.8, 49.1 & 
42.8, 49.1 
2 1.68 (1H, m) & 
1.48 (1H, dt, 13.8, 3) 
19.0 1.17, 1.48 & 
1.68, 1.61 
42.8, 39.1 & 
33.7, 38.1, 39.1 
3 1.17 (1H, dd, 3, 13.8) 
& 
1.39 (1H, m) 
42.8 1.68, 1.39 & 
1.17 
19.0, 24.1 & 
39.1, 49.1 
4  33.7   
5 1.27 (1H, s) 49.1 4.27 21.8, 24.1, 33.7, 38.1, 42.8, 71.6 
6 4.27 (1H, s) 71.8 1.27, 3.96 33.7, 38.1, 49.1, 71.6, 125.6 
7 3.96 (1H, s) 71.6 4.27 49.1, 71.8, 81.8, 125.6, 146.9 
8  125.6   
9  146.9   
10  38.1   
11 2.01 (1H, m) & 
1.95 (1H, m) 
21.3 1.61, 1.95 & 
1.61, 2.01, 1.39 
29.7, 40.0, 125.6, 146.9 & 
29.7, 38.1, 40.0, 125.6, 146.9 
12 1.61 (1H, m) & 
1.39 (1H, m) 
29.7 2.01, 1.95, 1.39 &  
1.61, 1.95 
21.3, 23.5, 40.0, 81.8, 143.9 & 
40.0 
13  40.0   
14 3.48 (1H, s) 81.8  23.5, 29.7, 40.0, 125.6, 143.9, 146.9 
15 5.72 (1H, dd, 11.1, 
17.4) 
143.9 5.05, 4.97 23.5, 29.7, 40.0, 81.8 
16 5.05 (1H, d, 17.4) & 
4.97 (1H, d, 11.1) 
112.7 5.72 & 
5.72 
40.0, 143.9 & 
40.0, 143.9 
17 1.10 (3H, s) 23.5  29.7, 40.0, 62.0, 81.8, 112.7, 143.9 
18 1.21 (3H, s) 24.1  33.4, 42.8, 49.1 
19 0.99 (3H, s) 33.4  24.1, 33.7, 42.8, 49.1 
20 1.32 (3H, s) 21.8  39.1, 49.1, 146.9 
21 3.54 (3H, s) 62.0  81.8 
 
 
 
Compound 25 was isolated as colorless amorphous solid, and HRESIMS and 13C NMR data 
determined its molecular formula as C22H36O3 (MW 348). Compound 24 and 25 have structural 
similarity except for the absence of hydroxyl and presence of methoxy at C-7 in 25. Instead of 
hydroxyl group, the presence of a methoxy group in 25 was in agreement with its HMBC 
correlations between the oxygenated methine [δH 3.26, s] and C-5, C-8, C-9, and C-21. 
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The relative configuration of 25 was assigned by comparing 13C NMR chemical shift with 
known compound kaempulchraol A4 and NOE correlations. C-6, C-10, C-13, and C-14 have 
almost similar 13C NMR chemical shift of 25 (δC 67.0, 38.0, 39.9, 88.2) and kaempulchraol A4 
(δC 66.1, 37.8, 40.2, 88.9), so hydroxyl at C-6 was β-axial and methyls at C-10 and C-13 were β-
axial and methoxy at C-14 was α-axially oriented (Fig. 6-15). Between H-5 and H-6, small 
axial-equatorial coupling constant indicated β-axial position of hydroxyl at C-6. In addition, 
axial H-5 and equatorial H-6 showed NOE correlations and H-5 was in α-axial. H-7 and H-14 
displayed equatorial-equatorial NOE correlations and so methoxy at C-7 was in α-axially 
oriented (Fig. 6-15). Thus, the structure of 25 was assigned as 7α,14α-dimethoxypimaradiene-
6β-ol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                         Fig. 6-14: 1H and 13C NMR of 25 
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Fig. 6-15: (a) COSY (Bold line) and Key HMBC (arrows) of 25; (b) structure of kaempulchraol 
A; (c) Chair conformation with NOE correlations of 25. 
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Table 6-17: NMR Spectroscopic data of compound 25 
 
 δH (J in Hz) (25) 
(600 MHz & CDCl3) 
 δC  (25) 
(150 MHz) 
COSY HMBC 
1 1.65 (2H, m) 39.5 1.50 42.5, 49.0 
2 1.65 (1H, m) & 
1.50 (1H, m) 
19.1 1.50, 1.36 & 
1.65 
42.5 & 
33.7, 38.0 
3 1.36 (2H, m) 42.5 1.65 24.4, 39.5 
4  33.7   
5 1.56 (1H, s) 49.0 4.39 22.4, 24.4, 33.7, 38.0, 42.5, 67.0, 147.3 
6 4.39 (1H, s) 67.0 1.56, 3.26 33.7, 38.0, 86.2, 123.8 
7 3.26 (1H, s) 86.2 4.39 49.0, 57.4, 67.0, 88.2, 123.8, 147.3 
8  123.8   
9  147.3   
10  38.0   
11 2.20 (1H, m) & 
1.99 (1H, m) 
20.2 1.28, 1.99 & 
1.28, 2.20 
39.9, 123.8, 147.3 & 
27.5, 39.9, 123.8, 147.3 
12 2.20 (1H, m) & 
1.28 (1H, m) 
27.5 2.20, 1.28 & 
2.20, 1.99 
20.6, 27.5, 39.9, 123.8, 147.3 
 
13  39.9   
14 2.98 (1H, s) 88.2  20.6, 27.5, 39.9, 60.4, 86.2, 123.8, 
147.3 
15 6.06 (1H, dd, 10.8, 17.4) 146.2 5.03, 5.00 20.6, 27.5, 39.9 
16 5.03 (1H, d, 17.4) & 
5.00 (1H, d, 10.8) 
111.6 6.06 & 
6.06 
39.9, 146.2 
17 0.86 (3H, s) 20.6  27.5, 39.9, 88.2, 146.2 
18 1.21 (3H, s) 24.4  33.7, 42.5, 49.0 
19 0.98 (3H, s) 33.1  24.4, 33.7, 42.5, 49.0 
20 1.32 (3H, s) 22.4  39.5, 49.0, 147.3 
21 3.45 (3H, s)  57.4  86.2 
22 3.39 (3H, s)  60.4  88.2 
 
 
 
Compound 26 was obtained as a colorless amorphous solid and its molecular formula was 
shown to be C22H36O3 (MW 348) by HRESIMS. The 1H and 13C NMR spectroscopic data of 26 
(Table 6-18) were similar to those of 25 except in the difference was orientation of methoxy 
group at C-14 (δH 3.40, s) as β, which was confirmed by the NOE correlations of OMe-14 to H3-
17 (δH 1.09, s).  
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The relative configuration of 26 was assigned by comparing 13C NMR chemical shift with 
known compound kaempulchraol B4 and NOE correlations. C-6, C-10, and C-13 have almost 
similar 13C NMR chemical shift of 26 (δC  66.6, 37.7, 40.1) and kaempulchraol B4 (δC  65.9, 37.4, 
40.5), so hydroxyl at C-6 was β-axial and methyls at C-10 and C-13 were β-axially oriented. 
Small axial-equatorial coupling constant between H-5 and H-6 also described the β-axial 
orientation of hydroxyl at C-6. Axial H-5, equatorial H-6, and methoxy proton at C-21 showed 
NOE correlations and so methoxy at C-7 was α-axially oriented. Axial H-14 and equatorial H-15 
showed NOE correlations and also axial H3-17 and methoxy proton at C-22 showed NOE 
correlations and so, methoxy at C-14 was in β-equatorial (Fig. 6-17). Thus, the structure of 26 
was assigned as 7α,14β-dimethoxypimaradiene-6β-ol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                             Fig. 6-16: 1H and 13C NMR of 26 
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Fig. 6-17: (a) COSY (Bold line) and Key HMBC (arrows) of 26; (b) structure of kaempulchraol 
B; (c) Chair conformation with NOE correlations of 26. 
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Table 6-18: NMR Spectroscopic data of compound 26 
 
 δH (J in Hz) (26) 
(600 MHz & CDCl3) 
 δC  (26) 
(150 MHz) 
COSY HMBC 
1 1.63 (2H, m) 39.1 1.46 19.0, 21.8, 37.7, 42.6, 49.3 
2 1.63 (1H, m) & 
1.46 (1H, dt, 13.8, 3.6) 
19.0  
1.63 
37.7, 39.1, 42.6 & 
33.6, 37.7, 42.6 
3 1.38 (1H, m) & 
1.17 (1H, dd, 3.6, 13.8) 
42.6 1.17 & 
1.38, 1.63 
19.0, 24.1, 39.1, 49.3 & 
19.0, 24.1, 33.6, 39.1 
4  33.6   
5 1.31 (1H, s) 49.3 4.38 21.8, 33.6, 39.1, 66.6, 80.8, 
146.6 
6 4.38 (1H, s) 66.6 1.31, 3.46 33.6, 37.7, 49.3, 80.8, 124.4 
7 3.46 (1H, s) 80.8 4.38 49.3, 57.8, 66.6, 81.8, 124.4, 
146.6 
8  124.4   
9  146.6   
10  37.7   
11 1.98 (1H, m) & 
1.94 (1H, dd, 6, 10.8) 
21.3 1.94, 1.38, 1.56 & 
1.98, 1.38, 1.56 
30.0, 40.1, 124.4, 146.6 & 
30.0, 40.1, 124.4, 146.6 
12 1.38 (1H, m) & 
1.56 (1H, ddd, 3, 6, 10.8) 
30.0 1.56, 1.98, 1.94 & 
1.38, 1.98, 1.94 
21.3, 81.8 & 
21.3, 23.2, 40.1, 81.8, 144.0 
13  40.1   
14 3.40 (1H, s) 81.8  23.2, 30.0, 40.1, 61.9, 80.8, 
124.4, 144.0, 146.6 
15 5.71 (1H, dd, 10.8, 17.4) 144.0 5.04, 4.95 23.2, 30.0, 40.1, 81.8 
16 4.95 (1H, d, 10.8) & 
5.04 (1H, d, 17.4) 
112.6 5.71 & 
5.71 
40.1, 144.0 & 
40.1, 144.0 
17 1.09 (3H, s) 23.2  30.0, 40.1, 81.8, 144.0 
18 1.20 (3H, s) 24.1  33.1, 42.6, 49.3 
19 0.99 (3H, s) 33.1  24.1, 33.6, 42.6, 49.3 
20 1.30 (3H, s) 21.8  21.3, 39.1, 37.7, 49.3, 146.6 
21 3.44 (3H, s)  57.8  80.8 
22 3.51 (3H, s)  61.9  81.8 
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Activity of isolated compounds 9-26 
Isolated compounds 9-26 from B. pandurata showed TRAIL-resistance overcoming activity, 
such as, 9 at 25 µM (42% difference), 10 at 80 µM (48% difference), 11 at 50 µM (32% 
difference), 12 at 20 µM (48% difference), 13 at 40 µM (50% difference), and 14 at 40 µM 
(49% difference), 15 at 30 µM (44% difference), 16 at 50 µM (40% difference), 17 at 80 µM 
(40% difference), 18 at 60 µM (48% difference), 19 at 30 µM (41% difference), and 20 at 10 
µM (46% difference), 21 at 30 µM (43% difference), 22 at 30 µM (44% difference), 23 at 80 
µM (52% difference), 24 at 60 µM (44% difference), 25 at 40 µM (48% difference), and 26 at 
30 µM (52% difference) respectively in TRAIL-resistant AGS cells (Fig. 6-18 and 6-19).  
 
Among these compounds, 9 at 25 µM, 12 at 20 µM, and 20 at 10 µM showed potent TRAIL-
resistance overcoming activity. 
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Fig. 6-18: TRAIL-resistance overcoming activity of compounds (9-17), Luteolin (positive 
control: Lut), and DMSO (negative control: Cont.) in the presence and absence of TRAIL on the 
viability of AGS cells. AGS cells were seeded in a 96-well culture plate (6 x 103 cells per well) 
for 24 h and then treated with indicated concentration of the compounds and TRAIL (100 
ng/mL) for 24 h. Viability was evaluated by the FMCA method. Data represent the means ± SD 
(n = 4). 
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Fig 6-19: TRAIL-resistance overcoming activity of compounds (18-26), Luteolin (positive 
control: Lut), and DMSO (negative control: Cont.) in the presence and absence of TRAIL on the 
viability of AGS cells. AGS cells were seeded in a 96-well culture plate (6 x 103 cells per well) 
for 24 h and then treated with indicated concentration of the compounds and TRAIL (100 
ng/mL) for 24 h. Viability was evaluated by the FMCA method. Data represent the means ± SD 
(n = 4) 
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To find out whether compound 9 exerted any cytotoxicity on non-cancer cells, we then 
examined the combined effect of TRAIL (100 ng/mL) and 9 (10, 20, 30, 40, and 50 μM) on 
human embryonic kidney (HEK293) cells, which showed no significant effect on viability at 10, 
20, and 30 μM (Fig. 6-20). Thus, it can be concluded that compound 9 decreased viability 
selectively in cancer cells without affecting non-cancer HEK293 cells upto 30 μM. 
 
                      
Fig 6-20: Cytotoxicity assay of compound 9, Luteolin (positive control: Lut), and DMSO 
(negative control: Cont.) in the presence and absence of TRAIL on the viability of HEK293 cells. 
HEK293 cells were seeded in a 96-well culture plate (6 x 103 cells per well) for 24 h and then 
treated with indicated concentration of the compound 9 and TRAIL (100 ng/mL) for 24 h. 
Viability was evaluated by the FMCA method. Data represent the means ± SD (n = 4). 
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Chapter 7: Effects of 4, 8, and 9 on TRAIL-mediated Proteins 
 
 
TRAIL is a potent and selective inducer of apoptosis in most of the cancer cells while sparing 
normal cells, and therefore has deserved intense interest as a promising agent for cancer therapy. 
In this study, xanthinosin (4), lasidiol p-methoxybenzoate (8), and 6β-
acetoxysandaracopimaradiene-1α,9α-diol (9) exhibited potent TRAIL-resistance overcoming 
activity, were selected for further studies using AGS cells, since a significant quantity of 4, 8, 
and 9 were isolated.  
 
Effects of 4 on TRAIL-induced apoptotic proteins 
In order to evaluate the effect of compound 4 against AGS cells, we investigated changes in the 
levels of the death receptors pathway related proteins using Western blotting analysis. It is well 
known that TRAIL interacts with the death receptors DR4 and DR5 to trigger apoptotic 
signaling and caspase-8 plays a central role in the apoptosis mediated by death receptors. 
Western blotting analysis after 24 h treatment of AGS cells with 4 induced a dose-dependent 
increased of DR4 and DR5 protein levels (Fig. 7-1). After the interaction of TRAIL with DR4 or 
DR5, the signals are transmitted into the cells through the functional cytoplasmic death domain 
which lead to the transformation of procaspase-8 into caspase-8. Proteolytic activation of 
caspase-8 further leads to two different apoptotic pathways. So, cleaved caspase-8 played a 
crucial role in apoptosis. Exposure of 4 for 24 h in AGS cells upregulated the levels of cleaved 
caspase-8 in a dose-dependent manner (Fig. 7-2). Cleaved caspase-8 or proteolytic activated 
caspase-8 further activates Bid, which in turn, translocates to mitochondria and activate 
mitochondrial pathway. In the mitochondrial pathways, death signals lead to change in the 
mitochondrial outer membrane permeability and releasing apoptosis inducing proteins Bax and 
Bak, subsequently releasing cytochrome c, which forms an apoptosome with Apaf-1 (apoptotic 
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protease activating factor 1) and caspase-9. Apaf-1 mediated proteolytic activation of caspase-9 
forms activated or cleaved caspase-9. Western blotting analysis showed that compound 4 
increased the levels of cleaved caspase-9 in a dose-dependent manner (Fig. 7-2). Cleaved 
caspase-9 then activates caspase 3/7. Caspase-3 is one of the key executioners of apoptosis and 
proteolytic activation of caspase-3 is the final stage of apoptosis. Western blotting analysis 
showed that 4 upregulated the levels of cleaved caspase-3 in a dose-dependent manner (Fig. 7-2).  
 
 
                                                    
                                                    
                                                    
                                                    
       
Fig. 7-1: Western blot analysis of DR4, DR5, and p53 protein levels in AGS cells after 24 h 
treatment with 4. The AGS cells were seeded in culture plate for 24 h and then treated with the 
indicated concentration of 4 for 24 h and then analyzed by Western blotting. β-actin was used as 
internal control. 
 
Previous study reported that dibenzylideneacetone (DBA),1 ginsenoside 20(S)-Rg3,2 and 
luteolin3 can increase the levels of cleaved caspase-8, cleaved caspase-9, and cleaved caspase-3 
in HCT116 and AGS cells. Another study reported that bortezomib can enhance the level of 
cleaved caspase-3 in RPMI 8226 and KMS-11 cells (bone marrow mononuclear cells).4 In our 
previous study, we reported that parviflorene F can increase the levels of cleaved caspase-8 in 
HeLa cells.5 In this study, we found that 4 enhanced the levels of cleaved caspase-8, 9, and 3 in 
a dose-dependent manner (Figure 7-2).  
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Fig. 7-2: Western blot analysis of Bax, Bcl-2, cleaved caspase-3, cleaved caspase-8, cleaved 
caspase-9, and CHOP protein levels in AGS cells after 24 h treatment with 4. The AGS cells 
were seeded in culture plate for 24 h and then treated with the indicated concentration of 4 for 24 
h and then analyzed by Western blotting. β-actin was used as internal control. 
 
To justify the relation of TRAIL with 4 in TRAIL-mediated apoptosis mechanism, we then 
examined the levels of cleaved caspase-8, -9, and -3 using 4 and TRAIL together by Western 
blotting analysis. The combined treatment of TRAIL and 4 at 8 μM in AGS cells for 24 h 
showed more prominent increase the levels of these caspases than 4 and TRAIL alone (Fig. 7-3). 
From Western blotting band intensity value analysis, we found that 4 (8 μM) and TRAIL 
together showed 100% enhancement of the levels of cleaved caspase-8, while 4 showed 10% 
and TRAIL showed 80% up-regulation of the levels of cleaved caspase-8. So, 4 showed 20% 
potentiation of cleaved caspase-8 levels with TRAIL (Fig. 7-3). 4 (8 μM) and TRAIL together 
exhibited 100% up-regulation of the levels of cleaved caspase-9, while 4 exhibited 20% and 
TRAIL exhibited 80% increment of  the levels of cleaved caspase-9. So, 4 showed 20% 
enhancement of cleaved caspase-9 levels with TRAIL (Fig. 7-3). 4 (8 μM) and TRAIL together 
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demonstrated 100% increment of the levels of cleaved caspase-3, while 4 showed 25% and 
TRAIL showed 35% up-regulation of the levels of cleaved caspase-3. So, 4 showed 65% 
potentiation of the levels of cleaved caspase-3 with TRAIL (Fig. 7-3). This study concluded that 
4 initiated the levels of cleaved caspase-8, 9, and 3 but, in the presence of TRAIL, 4 enhanced 
the levels of these caspases. According to Fig. 7-3, 4 potentiated the levels of cleaved caspase-3 
more with TRAIL than other caspases. Since proteolytic activation of caspase-3 is the final stage 
of apoptosis, 4 potentiated the TRAIL for inducing apoptosis. In addition, 4 significantly 
triggered the downregulation of cell survival protein Bcl-2 and up-regulation of mitochondrial 
membrane protein Bax in a dose-dependent manner (Fig. 7-2). Then we investigated the time 
dependent increase of DR4 and DR5 protein levels by compound 4 in 3, 6, and 12 h respectively. 
Western blotting analysis of 4 in AGS cells showed that compound 4 enhanced the levels of 
DR4 and DR5 in a time-dependent manner (Fig. 7-4). 
 
 
                                                                 
                                                                 
                                                                 
                                                                 
 
Fig. 7-3: Western blot analysis of combined effect of 4 and TRAIL on cleaved caspase-3, 
cleaved caspase-8, and cleaved caspase-9 protein levels in AGS cells. The AGS cells were 
seeded in culture plate for 24 h and then treated with the indicated concentration of 4, TRAIL, 
and 4 and TRAIL together for 24 h and then analyzed by Western blotting. The value under the 
band indicates the band intensity (%). β-actin was used as internal control. 
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The p53 protein played role in various cellular stresses by modulating transformation, cell 
growth, DNA synthesis and repair, differentiation, and apoptosis.6 p53, an important tumor 
suppressor protein, acts as a transcriptional factor of the proteins involved in the TRAIL signal.7  
p53 can induce the expression of Apaf 1 as well as TRAIL receptors DR4 and DR5 and pro-
apoptotic mitochondrial membrane proteins Bax and Bak. Expression of certain anti-apoptotic 
genes such as Bcl-2, Bcl-xl, and survivin can be suppressed by p53.6 Previous study reported 
that p53 induced DR5.8 In the present study, we investigated p53 protein level by Western blot 
analysis and the result showed that 4 enhanced the p53 protein level in a dose-dependent manner 
in TRAIL-resistant AGS cells (Fig. 7-1).  
 
Previous study reported that CHOP influenced DR5 for TRAIL-induced apoptosis.9 CHOP is 
known to endoplasmic reticulum (ER) stress marker protein involved in ER stress-mediated 
apoptosis.10 Western blotting analysis result showed that 4 upregulated the levels of CHOP 
protein in a dose-dependent manner (Fig. 7-2). 
 
 
                                                    
                                                    
                                                    
 
Fig. 7-4: Western blot analysis of DR4 and DR5 protein levels in AGS cells after 3, 6, and 12 h 
treatment of 4 at 8 μM. The AGS cells were seeded in culture plate for 24 h and then treated 
with the 4 for 3, 6, and 12 h and then analyzed by Western blotting. DMSO was used as control. 
β-actin was used as internal control. 
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                    Fig. 7-5: Effect of 4 on TRAIL-mediated apoptotic pathway 
 
Effects of 8 on TRAIL-induced apoptotic proteins 
To justify cellular mechanism involving the synergistic effect of 8 and TRAIL in AGS cells, we 
observed that the treatment of AGS cells with 8 for 24 h induced a dose-dependent increased in 
the DR4 and DR5 protein levels (Fig. 7-6). Exposure of 8 in AGS cells for 24 h up-regulates the 
levels of cleaved caspase-8 in a dose-dependent manner (Fig. 7-7). Western blotting analysis 
result exhibited that 8 increased the levels of mitochondrial membrane protein Bax in a dose-
dependent manner (Fig. 7-7). 24 h treatment of AGS cells with 8, and after that Western blotting 
analysis exhibited that 8 enhanced the levels of cleaved caspase-9 and cleaved caspase-3 in a 
dose-dependent manner (Fig. 7-7). We found that 8 increased the levels of cleaved caspase-8, 
cleaved caspase-9, and cleaved caspase-3 in a dose-dependent manner (Fig. 7-7). 
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Fig. 7-6: Western blot analysis of DR4, DR5, and p53 protein levels in AGS cells after 24 h 
treatment with 8. The AGS cells were seeded in culture plate for 24 h and then treated with the 
indicated concentration of 8 for 24 h and then analyzed by Western blotting. β-actin was used as 
internal control. 
 
To rationalize the relation of 8 with TRAIL in TRAIL-induced apoptosis mechanism, we 
examined the levels of cleaved caspase-8, cleaved caspase-9, and cleaved caspase-3 using 8 and 
TRAIL together by Western blotting analysis. The result showed that the combined treatment of 
TRAIL and 8 at 16 μM in AGS cells for 24 h exhibited more prominent enhancement the levels 
of cleaved caspase-8, cleaved caspase-9, and cleaved-3 than 8 and TRAIL alone (Fig. 7-8). 
According to Western blotting band intensity value analysis from Fig. 6-8, we found that 8 (16 
μM) and TRAIL together showed 100% increment of the levels of cleaved caspase-8, while 8 
exhibited 10% and TRAIL showed 50% upregulation of the levels of cleaved caspase-8. So, 8 
displayed 50% potentiation of cleaved caspase-8 levels with TRAIL. 8 (16 μM) and TRAIL 
together showed 100% raising the levels of cleaved caspase-9, while only 8 exhibited 15% and 
TRAIL displayed 80% increment of the levels of cleaved caspase-9. So, 8 showed 20% 
enhancement of cleaved caspase-9 levels with TRAIL (Fig. 7-8). 8 (16 μM) and TRAIL together 
demonstrated 100% upregulation of the levels of cleaved caspase-3, while 8 showed 5% and 
TRAIL exhibited 30% increment of the levels of cleaved caspase-3. So, 8 potentiated 70% of the 
levels of cleaved caspase-3 with TRAIL (Fig. 7-8). These results concluded that 8 potentiated 
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the levels of cleaved caspase-3 more with TRAIL than other caspases. Since activated caspase-3 
is the executioner of apoptosis, 8 induced the TRAIL for apoptosis. Apoptosis inhibitor protein 
Bcl-2 over-expression blocks the mitochondrial changes associated with cell death. Western 
blotting analysis showed that 8 downregulated the level of Bcl-2 in a dose-dependent manner 
(Fig. 7-7). 8 also upregulated the levels of tumor necrosis protein p53 (Fig. 7-6) and 
endoplasmic reticulum (ER) stress inducing protein CHOP (Fig. 7-7) in a dose-dependent 
manner in AGS cells.  
 
 
 
 
  
                                                             
 
                                                             
 
                                                             
 
                                                             
 
                                                             
 
                                                             
 
 
Fig. 7-7: Western blot analysis of Bax, Bcl-2, cleaved caspase-3, cleaved caspase-8, cleaved 
caspase-9, and CHOP protein levels in AGS cells after 24 h treatment with 8. The AGS cells 
were seeded in culture plate for 24 h and then treated with the indicated concentration of 8 for 24 
h and then analyzed by Western blotting. β-actin was used as internal control. 
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Fig. 7-8: Western blot analysis of combined effect of 8 and TRAIL on cleaved caspase-3, 
cleaved caspase-8, and cleaved caspase-9 protein levels in AGS cells. The AGS cells were 
seeded in culture plate for 24 h and then treated with the indicated concentration of 8, TRAIL, 
and 8 and TRAIL together for 24 h and then analyzed by Western blotting. The value under the 
band indicates the band intensity (%). β-actin was used as internal control. 
 
 
                         
                              Fig. 7-9: Effect of 8 on TRAIL-mediated apoptotic pathway 
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Effects of 9 on TRAIL-induced apoptotic proteins 
Compound 9 showed potent TRAIL-resistance overcoming activity at 25 µM, were selected for 
further studies using AGS cells, since a significant quantity of 9 was isolated. To find out 
intracellular apoptotic mechanism of 9 against AGS cells, we investigated levels of TRAIL-
induced apoptotic related proteins using Western blotting analysis. To assess the synergistic 
induction of apoptosis by the combined treatment of 9 and TRAIL in AGS cells, we found that 
Western blotting analysis after 24 h treatment of AGS cells with 9 induced DR4 and DR5 
protein levels in a dose-dependent manner (Fig. 7-10).  TRAIL-induced apoptosis started after 
binding of TRAIL with DR4 and DR5 receptors, and then the signals transmitted into the cells 
through the functional cytoplasmic Fas associated death domain (trimerization of Fas and pro-
caspase-8) which lead to the transformation of procaspase-8 into caspase-8. Western Blotting 
analysis showed that 9 enhanced the level of Fas in a dose-dependent manner (Fig. 7-10). 
Proteolytic activation of caspase-8 further leads to two different apoptotic pathways. So, cleaved 
caspase-8 plays a significant role in cell apoptosis. Western blot analysis exhibited that 9 
upregulated the levels of cleaved caspase-8 in a dose-dependent manner (Fig. 7-11).  
 
Cleaved caspase-8 or proteolytic activated caspase-8 further activates Bid, which in turn, 
translocates to mitochondria and activate mitochondrial pathway. In the mitochondrial pathways, 
death signals lead to change in the mitochondrial outer membrane permeability by releasing 
mitochondrial membrane protein Bax and Bak, subsequently releasing cytochrome c, which 
forms an apoptosome with Apaf-1 (apoptotic protease activating factor 1) and caspase-9. Apaf-1 
mediated proteolytic activation of caspase-9 forms activated or cleaved caspase-9. Western 
blotting analysis showed that 9 upregulated the levels of Bax and cleaved caspase-9 in a dose-
dependent manner (Fig. 7-11). Cleaved caspase-9 then activates caspase 3/7. Caspase-3 is one of 
the key executioners of apoptosis and proteolytic activation of caspase-3 is the final stage of 
apoptosis. Treatment of AGS cells with 9 for 24 h increased the levels of cleaved caspase-3 in a 
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dose-dependent manner (Fig. 7-11). In this study, we found that 9 enhanced the levels of cleaved 
caspase-8, -9, and -3 in a dose-dependent manner (Fig. 7-11). Since proteolytic activation of 
caspase-3 is the final stage of apoptosis, 9 potentiated the TRAIL for inducing apoptosis.  
 
 
                                                       
                                                       
                                                        
                                                       
                                                       
                                                       
                                                    
Fig. 7-10: Western blot analysis of DR4, DR5, p53, Fas, and CHOP protein levels in AGS cells 
after 24 h treatment with 9. The AGS cells were seeded in culture plate for 24 h and then treated 
with the indicated concentration of 9 for 24 h and then analyzed by Western blotting. β-actin 
was used as internal control. 
 
 
Caspase-8 is a critical mediator for death receptor-induced apoptosis and GSK-3β suppresses the 
activity of caspase-8. GSK-3β inhibitor induced TRAIL sensitization depends on caspase-8 
activities.11 Western blotting result showed that 9 significantly triggered the downregulation of 
cell survival protein Bcl-2 and GSK-3β in a dose-dependent manner (Fig. 7-11). In addition, 9 
enhanced the levels of death receptors inducing proteins p53 and CHOP in a dose-dependent 
manner in AGS cells (Fig. 7-10).  
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Fig. 7-11: Western blot analysis of GSK-3β, Bcl-2, Bax, Cleaved caspase-3, -8, and -9 protein 
levels in AGS cells after 24 h treatment with 9. The AGS cells were seeded in culture plate for 
24 h and then treated with the indicated concentration of 9 for 24 h and then analyzed by 
Western blotting. β-actin was used as internal control. 
 
 
c-FLIP (cellular FLICE-Like Inhibitory Protein) is an antagonist of caspases-8 and -10, 
preventing the binding of these caspases with DISC (Death Inducing Signaling Complex) and 
thus inhibiting the autolytic cleavage and subsequent activation of caspase-8.12 c-FLIP is 
expressed in various tumor cells and its expression is associated with enhanced tumorigenicity 
and poor clinical outcome in many types of cancers because of TRAIL-resistance. Treatment of 
9 alone significantly downregulated the level of c-FLIP in AGS cells (Fig. 7-12). From this 
study, we found that the subtoxic doses of 9 sensitized human gastric adenocarcinoma (AGS) 
cells to TRAIL-induced apoptosis by downregulating c-FLIP protein level.   
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Fig. 7-12: Western blot analysis of c-FLIP protein levels in AGS cells after 24 h treatment with 
9. The AGS cells were seeded in culture plate for 24 h and then treated with the indicated 
concentration of 9 for 24 h and then analyzed by Western blotting. β-actin was used as internal 
control. 
 
 
                                                          
                                                          
                                                          
                                                          
 
Fig. 7-13: Western blot analysis of combined effect of 9 and TRAIL on cleaved caspase-3, 
cleaved caspase-8, and cleaved caspase-9 protein levels in AGS cells. The AGS cells were 
seeded in culture plate for 24 h and then treated with the indicated concentration of 9, TRAIL, 
and 9 and TRAIL together for 24 h and then analyzed by Western blotting. The value under the 
band indicates the band intensity (%). β-actin was used as internal control. 
 
 
To rationalize the relation of TRAIL with 9 in TRAIL-inducing apoptosis mechanism, we then 
studied the levels of cleaved caspase-8, -9, and -3 using 9 and TRAIL together by Western 
blotting analysis. We found that the combined treatment of TRAIL (100 ng/mL) and 9 at 16 µM 
in AGS cells for 24 h showed remarkable rising the levels of cleaved caspase-8, -9, and -3 than 9 
and TRAIL alone (Fig. 7-13). From Western blotting band intensity value analysis, we found 
that 9 potentiated the activity of cleaved caspase-8, -9, and -3 with 65, 75, and 68% respectively 
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with TRAIL (Fig. 7-13). This study concluded that 9 initiated the levels of cleaved caspase-8, 9, 
and 3 but, in the presence of TRAIL, 9 remarkably enhanced the levels of these caspases. Since 
proteolytic activation of caspase-8, -9, and -3 played significant role in TRAIL induced 
apoptosis, 9 influenced the TRAIL for inducing apoptosis in AGS cells. 
 
 
                         Fig. 7-14: Effect of 9 on TRAIL-mediated apoptotic pathway 
 
From the above discussion we can conclude that compound 4, 8, and 9 upregulated the levels of 
apoptosis inducing protein such as DR4, DR5, CHOP, Fas, Bax, cleaved caspase-8, cleaved 
caspase-9, cleaved caspase-3, and p53 and downregulated the levels of cell survival protein such 
as Bcl-2, c-FLIP, and GSK-3β in a dose-dependent manner in TRAIL-resistant AGS cells.  
 
 
 
105 
 
References 
 
1. Prasad, S.; Yadav, V. R.; Ravindran, J.; Aggarwal, B. B. Cancer Res. 2011, 71, 538-549. 
2. Park, E. H.; Kim, Y. J.; Yamabe, N.; Park, S. H; Kim, H. K.; Jang, H. J.; Kim, J. H.; Cheon, 
G. J.; Ham, J.; Kang, K. S. J. Ginseng Res. 2014, 38, 22-27. 
3. Wu, B.; Zhang, Q.; Shen, W.; Zhu, J. Mol. Cell Biochem. 2008, 313, 125-132. 
4. Miki, H.; Nakamura, S.; Oda, A.; Amachi, R.; Watanabe, K.; Hanson, D.; Teramachi, J.; 
Hiasa, M.; Yagi, H.; Sogabe, K.; Takahashi, M.; Maruhashi, T.; Udaka, K.; Harada, T.; Fuji, 
S.; Nakano, A.; Kagawa, K.; Ri, M.; Iida, S.; Ozaki, S.; Matsumoto, T.; Abe, M. Int. J. 
Myelom. 2015, 5, 1-7. 
5. Ohtsuki, T.; Tamaki, M.; Toume, K.; Ishibashi, M. Bioorg. Med. Chem. 2008, 16, 1756-
1763. 
6. Wu, G. S. Cancer Lett. 2009, 285, 1-5. 
7. Zhao, J.; Lu, Y.; Shen, H. M. Cancer Lett. 2012, 314, 8-23.  
8. Wu, G. S.; Burns, T. F.; McDonald, E. R., 3rd; Jiang, W.; Meng, R.; Krantz, I. D.; Kao, G.; 
Gan, D. D.; Zhou, J. Y.; Muschel, R.; Hamilton, S. R.; Spinner, N. B.; Markowitz, S.; Wu, 
G.; el-Deiry, W. S. Nat. Genet. 1997, 17, 141-143. 
9. Gupta, S. C.; Sajin, F. K.; Nair, M. S.; Mo, Y. Y.; Aggarwal, B. B. J. Biol. Chem. 2013, 288, 
32343-32356. 
10. Yang, J. F.; Cao, J. G.; Tian, L.; Liu, F. Cancer Chemother. Pharmacol. 2012, 69, 195-206. 
11. Liabo, X.; Zhang, L.; Thrasher, B. Mol. Cancer Ther. 2003, 2, 1215-1222. 
12. Piggott, L.; Omidvar, N.; Perez, S. M.; Eberl, M.; Clarkson, R. W. E. Breast Cancer Res. 
2011, 13, 2-15. 
 
 
 
 
 
106 
 
 
Chapter 8: Conclusion 
 
 
Bioassay-guided fractionation led to the isolation of 26 compounds from D. stramonium (1-3), X. 
strumarium (4-8), and B. pandurata (9-26). Compounds 1-3 are alkaloids, 4-8 are sesquiterpenes 
lactones, 9-22 and 24-26 are pimarane diterpenes and 23 is a limonene type compound. 
Compounds 5 and 6 were first isolated from natural resources. Compounds 17-20, 22, and 24-26 
are new compounds and remaining are known compounds. All compounds 1-26 exhibited 
TRAIL-resistance overcoming activity in TRAIL-resistant AGS cells. Among them, compounds 
4-8, 9, 12, and 20 showed potent activity at 8, 20, 20, 16, 16, 25, 20, and 10 µM respectively in 
TRAIL-resistant AGS cells. Subtoxic doses of compound 4, 8, and 9 sensitize AGS cells to 
TRAIL-induced apoptosis by upregulating apoptosis inducing proteins, such as, DR4, DR5, p53, 
Fas, CHOP, Bak, cleaved caspase-3, -8, and -9 and downregulated the levels of cell survival 
proteins, such as, Bcl-2, c-FLIP, and GSK-3β in TRAIL-resistant AGS cells. Compound 4 and 9 
did not decrease viability in non-cancer (HEK293) cells up to 8 and 30 µM respectively. In 
addition, compound 4 showed TRAIL-resistance overcoming activity in HeLa, DU145, DLD1, 
and MCF7 cells. 
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Chapter 9: Experimental 
 
 
General 
Column chromatography: PSQ 100B, FUJI SILYSIA CHEMICAL LTD. 
      Chromatorex ODS, FUJI SILYSIA CHEMICAL LTD. 
      Diaion HP-20, Mitsubashi Chemical 
      Sephadex LH-20, GE healthcare 
      Silica gel 60N, Kanto Chemical 
TLC plate  : Kieselgel 60 F254, Merck and RP (Reverse phase) 18 F254, Merck. 
Developing reagent : 10% H2SO4, Phosphomolybdate, and Dragendroff’s. 
Optical rotation : JASCO P-1020 polarimeter 
UV spectra   : Shimadzu UV mini-1240 spectrometer 
NMR spectra  : JEOL ECP400, ECP600, ECS400, ECA600 spectrometers 
(deuterated solvents, the chemical shift of which was used as an    internal 
standard) 
HPLC   : JASCO 
HRESIMS  : JEOL JMS-T100LP 
Incubator  : CO2 MCO-17A1, SANYO 37 °C and 5% CO2. 
Clean bench  : Bio Clean Bench MCV-B131S, SANYO 
  Bio Clean Bench MCV-B710A TS, SANYO 
Centrifuge  : SORVALLR Biofuge fresco (13000 rpm), Kendro  
     Hitachi Koki CT15RE 
Fluorometer  : Fluoroskan Ascent (Thermo Fisher Scientific, Waltham, MA, USA) 
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Cells Culture 
Cells: 
Human Gastric Adenocarcinoma (AGS) cells, HeLa (cervical cancer) cells, and Human 
Embryonic Kidney (HEK293) cells were purchased from ATCC (American Type Culture 
Collection), USA. 
DU146 (prostate cancer) cells were derived from the Institute of Development, Aging and 
Cancer, Tohoku University, Japan. 
MCF7 (breast cancer) cells were collected from the RIKEN BRC Cell Bank. 
DLD1 (colorectal cancer) cells were a generous gift from Dr. Bingliang Fang (The University of 
Texas M. D. Anderson Cancer Centre, USA). 
 
Culture Medium: 
AGS cells, DU145 cells and DLD1 cells were cultured in Roswell Park Memorial Institute 
(RPMI)-1640 medium (Wako, Osaka, Japan) with fetal bovine serum (10% FBS) and 1% 
penicillin-streptomycin. HeLa cells, MCF7 cells and HEK293 cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) with fetal bovine serum (10% FBS). Cultures were 
maintained in a humidifier incubator at 370C in 5% CO2/95% air. 
 
Fetal Bovine Serum (FBS, Biowest), Trypsin EDTA (0.25% Trypsin-EDTA, Gibco), Trypan 
blue (0.4% (w/v) trypan blue, Nacalai tesque Inc.). 
PBS (Phosphate Buffer Saline): 
KCl (Nacalai tesque Inc.)  0.2 g 
KH2PO4 (Nacalai tesque Inc.) 0.2 g 
NaCl (Nacalai tesque Inc.)  8.0 g 
Na2HPO4 (Nacalai tesque Inc.) 1.11 g 
dH2O      up to 1 L (autoclaved; 1210C, 20 min) 
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Western blotting 
Electrophoresis apparatus : BE-201, BIO CRAFT 
       Mini-PROTEAN Tetra Cell, BIO-RAD 
Transfer System  : Trans-Blot SD Semi-DryTransfer cell, BIO-RAD 
      Trans-Blot Tubo, BIO-RAD 
Detection   : BIO-RAD (ChemiDocTM XRS+) 
Gel-Blotting Paper  : GE Healthcare Science 
Membrane   : Immuno-Blot PVDF membrane, BIO-RAD 
  
Sodiumdodecylsulfate polyacrylamide gel (SDS-PAGE) 
 Running Gel Stacking Gel 
12.5% 
15-60 KDa 
10% 
30-70 KDa 
7.5% 
50-200 KDa 
5% 
dH2O 3.30 mL 4.65 mL 5.85 mL 2.7 mL 
30% Acrylamide 6.30 mL 4.95 mL 3.75 mL 0.66 mL 
1M Tris-HCl (pH 8.8) 5.1 mL 5.1 mL 5.1 mL  
1M Tris-HCl (pH 6.8)    0.50 mL 
10% SDS 0.15 mL 0.15 mL 0.15 mL 40 µL 
10% APS 0.1 mL 0.1 mL 0.1 mL 40 µL 
TEMED 7 µL 7 µL 7 µL 4 µL 
TEMED: Tetramethylethylenediamine 
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10 X Running Buffer: 
Tris   30.3 g (0.25 M) 
Glycine  144 g (1.92 M) 
SDS   10 g (1 % (w/v)) 
dH2O   up to 1 L 
 
Transfer Buffer: 
Tris   2.9 g  (48 mM) 
Glycine  1.5 g  (39 mM) 
MeOH  100 mL (20% (w/w)) 
dH2O   up to 500 mL 
 
5 X Sample Buffer: 
 0.5 M Tris-HCl (pH 6.8) 15.7 mL (0.313 M) 
 SDS (Sodiumdodecylsulfate) 2.5 g [10% (v/v)] 
 Sucrose (Nacalai tesque Inc.) 6.25 g [25% (v/v)] 
 Bromo phenol blue (Kanto) 6.25 mg [0.025% (v/v)] 
 dH2O    up to 25 mL 
 
TBST (Tris-Buffered Saline Tween 20): 
Tris   3.6 g 
NaCl   17.4 g 
conc.HCl  2.4 mL 
Tween 20  3.0 g 
dH2O   up to 3 L 
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Lysis Buffer: 
1M Tris-HCl    2 mL (20 mM) 
NaCl     878 mg (150 mM) 
Triton X-100    0.5 mL [0.5 % (w/v)] 
sodium deoxycholate   500 mg [0.5 % (w/v)] 
EDTA    292.2 mg (10 mM) 
sodium orthovanadate (Na3VO4) 18.4 mg (1 mM) 
sodium fluoride (NaF)  0.42 mg (0.1 mM) 
protease inhibitor cocktail  1 mL (1 % (v/v)) 
dH2O     up to 100 mL 
 
30% Acrylamide: 
Acrylamide    29.2 mg 
N,N’-methylene-bis-acrylamide 0.8 g 
dH2O     up to 100 mL 
 
10% Sodium dodecylsulfate (SDS) 
 SDS   5 g 
 dH2O   up to 50 mL 
 
10% Ammonium persulfate (APS) 
 APS   100 mg 
 dH2O   up to 1 mL 
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Stripping buffer 
 1 M Tris-HCl (pH 6.8)  3.13 mL (62.5 mM) 
 10% SDS    10 mL [2% (v/w)] 
 2-mercaptoethanol   349 μL (100 mM) 
 dH2O     up to 50 mL 
 
Western Blotting Protocol 
 
 
Day 1: AGS Cells seeding 106 Cells/10 ml dish  
Day 2: Sample application 
Day 3: Cells wash by ice cool PBS & then Cells scraping and taken in Eppendorf tube. 
 Centrifuge – 5000 rpm, 10 min., 40 C temp. 
 Aspirate PBS & add 1 ml PBS & then vortex 
 Centrifuge – 5000 rpm, 10 min., 40 C temp. 
 Aspirate PBS & add 100 μL lysis buffer & then vortex 
 Keep 30min.on ice 
 Centrifuge – 13000 rpm, 30 min., 40 C temp. 
 Move supernatant to new Eppendorf tube 
 Then SDS-PAGE gel was prepared. 
 Protein concentration was measured by Nanodrop Machine. 
 Sample was prepared 10 μL – lysate protein (8 μL) + prepared sample buffer (2 μL) 
 Blank was prepared by lysis buffer & prepared sample buffer 
 Heating sample & blank for 3 min. at 1000 C temp. 
 Then apply sample, marker protein & blank on the gel chamber that was prepared by gel 
comb. 
 1X running buffer was added and then connected to voltage machine 
 For stacking gel – 150 volt & 20 amp. and for running gel – 200 volt & 30 amp. 
 PVDF membrane & gel blotting paper were first activated my MeOH and then put in 
transfer buffer for 1 hr and shaking. 
 After finishing gel electrophoresis, gel was removed from machine and protein blot was 
transferred to PVDF membrane by TransBlot machine. 
 Then membrane was cut according to size of detection protein 
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 Wash the membrane by TBST for three times & put the membrane in 5% skimmed milk for 
1 hr and then again wash by TBST for three times 
 Then put the membrane in primary antibody containing 5% skimmed milk. 
 For DR5 and DR4 – 4: 2000 μL in 5% skimmed milk. 
 For cleaved caspase-3, cleaved caspase-8, cleaved caspase-9, Bcl-2, Bax, Fas, GSK-3β, 
CHOP, p53 & c-FLIP – 2: 2000 μL in 5% skimmed milk 
 For beta-actin detection – 0.5: 2000 μL in 5% skimmed milk 
 PVDF membrane is put in the primary antibody containing 5% skimmed milk for 12 hrs for 
DR4, DR5, p53, CHOP, Fas, GSK-3β, cleaved caspase-8, cleaved caspase-9, & c-FLIP and 
1 hr for beta-actin. 
 Then membrane was removed from primary antibody and wash by TBST for three times 
 Again put the membrane in the secondary antibody containing 5% skimmed for 1 hr 
 For secondary antibody – 0.5: 2000 μL in 5% skimmed milk 
 Then PVDF membrane was removed from skimmed milk and again wash by TBST for three 
times 
 Western blot detection solution was prepared by mixing equal amount of two types solution 
A and B. 
 Then detection solutions were added on the PVDF membrane and detect the protein 
expression by BioRad ChemiDoc Image machine.  
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Plant Material 
 
Medicinal Plants Collected from Bangladesh 
The leaves of Datura stramonium (KKB186) and Xanthium strumarium (KKB255) were 
collected from Natore, Bangladesh by Professor Dr. Samir Kumar Sadhu, Pharmacy Discipline, 
Khulna University, Bangladesh and Professor Dr. Firoj Ahmed, Department of Pharmaceutical 
Chemistry, Dhaka University, Bangladesh and also by me. Voucher specimens have been 
deposited at the Laboratory of Natural Products Chemistry, Graduated School of Pharmaceutical 
Sciences, Chiba University, Japan. 
 
Medicinal Plants Collected from Thailand 
The rhizomes of Boesenbergia pandurata was collected from Thailand. The Plant was identified 
by Dr. Thaworn Kowithayakorn, and a voucher specimen (KKP87) has been deposited at the 
Laboratory of Natural Products Chemistry, Graduated School of Pharmaceutical Sciences, Chiba 
University, Japan. 
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Appendix-I 
1D and 2D NMR Spectrum of New Compounds (17-20, 22, and 24-26) 
 
 
 
 
 
 
 
 
1H NMR Spectrum of 17 (CD3OD) 
13C NMR Spectrum of 17 (CD3OD) 
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COSY Spectrum of 17 (CD3OD) 
HMQC Spectrum of 17 (CD3OD) 
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HMBC Spectrum of 17 (CD3OD) 
1H NMR Spectrum of 18 (CDCl3) 
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13C NMR Spectrum of 18 (CDCl3) 
COSY Spectrum of 18 (CDCl3) 
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HMQC Spectrum of 18 (CDCl3) 
HMBC Spectrum of 18 (CDCl3) 
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1H NMR Spectrum of 19 (CDCl3) 
13C NMR Spectrum of 19 (CDCl3) 
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COSY Spectrum of 19 (CDCl3) 
HMQC Spectrum of 19 (CDCl3) 
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HMBC Spectrum of 19 (CDCl3) 
1H NMR Spectrum of 20 (CDCl3) 
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13C NMR Spectrum of 20 (CDCl3) 
COSY Spectrum of 20 (CDCl3) 
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HMQC Spectrum of 20 (CDCl3) 
HMBC Spectrum of 20 (CDCl3) 
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1H NMR Spectrum of 22 (CDCl3) 
13C NMR Spectrum of 22 (CDCl3) 
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COSY Spectrum of 22 (CDCl3) 
HMQC Spectrum of 22 (CDCl3) 
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HMBC Spectrum of 22 (CDCl3) 
1H NMR Spectrum of 24 (CDCl3) 
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13C NMR Spectrum of 24 (CDCl3) 
COSY Spectrum of 24 (CDCl3) 
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HMQC Spectrum of 24 (CDCl3) 
HMBC Spectrum of 24 (CDCl3) 
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1H NMR Spectrum of 25 (CDCl3) 
13C NMR Spectrum of 25 (CDCl3) 
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COSY Spectrum of 25 (CDCl3) 
HMQC Spectrum of 25 (CDCl3) 
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HMBC Spectrum of 25 (CDCl3) 
1H NMR Spectrum of 26 (CDCl3) 
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13C NMR Spectrum of 26 (CDCl3) 
COSY Spectrum of 26 (CDCl3) 
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HMQC Spectrum of 26 (CDCl3) 
HMBC Spectrum of 26 (CDCl3) 
